Title of Invention	"A METALLOPROTEINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME"
Abstract	A metalloproteinase inhibitor compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof

Full Text

The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. Metalloproteinases are a superfaraily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes have been classified into families and subfamilies as described in N.M. Hooper (1994) FEES Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMPs) such as the collagenases (MMPl, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (1MMP3. MMPIO, MMPll), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMPl 9), the MT-MMPs (MMP14, MMP15, MMP16, MMP17); the reprolysin or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM 10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family. Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of biological important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper et al., (1997) Biochem J. 321:265-279). Metalloproteinases have been associated with many diseases or conditions. Inhibition of the activity of one or more metalloproteinases may well be of benefit in these diseases or conditions, for example: various inflammatory and allergic diseases such as, inflanunation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastro-intestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflanmiation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dennal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atheroscelerosis; asthma; rhinitis; and chronic obstructive pulmonary diseases (COPD). MMP12, also known as macrophage elastase or metalloelastase, was initially cloned in the mouse by Shapiro et al [1992, Journal of Biological Chemistry 267: 4664] and in man by the same group in 1995. MMP12 is preferentially expressed in activated macrophages, and has been shown to be secreted from alveolar macrophages from smokers [Shapiro et al, 1993, Journal of Biological Chemistry, 268: 23824] as well as in foam cells in atherosclerotic lesions [Matsuraoto et ah 1998, Am J Pathol J53: 109]. A mouse model of COPD is based on challenge of mice with cigarette smoke for six months, two cigarettes a day six days a week. Wildtype mice developed pulmonary emphysema after this treatment. When MMP12 knock-out mice were tested in this model they developed no significant emphysema, strongly indicating that MMP12 is a key enzyme in the COPD pathogenesis. The role of MMPs such as MMP12 in COPD (emphysema and bronchitis) is discussed in Anderson and Shinagawa, 1999, Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs illl: 29-38. It was recentty discovered that smoking increases macrophage infiltration and macrophage-derived MMP-I2 expression in human carotid artery plaques Kangavari [Matetzky S, Fishbein MC et al, Circulation 102:(l8). 36-39 Suppl. S. Oct 31,2000]. A number of metalloproteinase inhibitors are known (see for example the reviews of MMP inhibitors by Beckett R.P. and Whittaker M., 1998, Exp. Opin. Ther. Patents, 8(3):259-282. and by Whittaker M. et al, 1999, Chemical Reviews 99(9):2735-2776). Published International Patent Application No. WO 02/096426 (Bristol- Myers Squibb Company) describes hydantoin derivatives of formula (Formula Removed) in which the substituents R1R2,R3,R4,R5R6,R7 and R11 are broadly defined. The derivatives are said, in general terms, to act as inhibitors of metalloproteinases, in particular TACE, MMPs and/or aggrecanase, although no data demonstrating biological activity is included in the application. We have now discovered a new class of compounds that are potent and selective MMP12 inhibitors and have desirable activity profiles, in particular they are highly selective inhibitors for MMP12 relative to, for example, MMP14, MMP19 and TACE. In accordance with the present invention, there is therefore provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof (Formula Removed) wherein represents an oxygen atom or a group NR or CH2; Y represents NH or N-methyl; Z1 and Z2 each independently represent an oxygen or sulphur atom, provided that at least one of Z1 and Z2 represents an oxygen atom; Either R represents hydrogen or a group selected from C1-C6, alkyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, carboxyl, -NR5R6, -CONR7,R8 C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylcarbonyl(oxy), -S(0)rnC1-C6 alkyl where m is 0,1 or 2, C1-C6 alkylsulphonylamino, C1-C6 alkoxycari)onyl(amino), benzyloxy and a saturated or unsaturated 5- to 6- membered ring which may comprise at least one ring heteroatom selected from aitrogen. oxygen and sulphur, the ring in turn being optionally substituted with at least one substituent selected from halogen, hydroxyl, 0x0 (=0), carboxyl, cyano, C1-C6 alkyl, C1-C6 alkoxycarbonyl and C1-C6 hydroxyalkyl, R2 represents hydrogM or C1-C6, alkyl, and R3 represents hydrogen or C1-C6 alkyl, or Rand R2 together with the carbon atoms to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R3 is as defined above, or R2 and R3 togethear with the carbon atom to which they are attaciied form a saturated 5- to 6-mcmbered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R is as defined above; R4 represents hydrogen or C1-C6 alkyl; R , R , R and R each independently represent hydrogen or C1-C6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C1-C6 alkoxy; L represents -CH2C(0)- or -C(0)CH2-, or L represents a C2-C5 alkyl or C2-C6 alkynyl group optionally interrupted or terminated by at least one moiety selected from O, NH, S, SO, SO2 and C(0), or L represents a C3-C6 cycloalkyl, methylC3-C6 cycloalkyl or C3-C6 cycloalkylmethyl group, each of the recited groups being optionally substituted with at least one substituent selected from hydroxyl, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy, or L represents a C3-C4 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G2 to form a ring; G2 represents a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C1-C6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C2-C6 alkenyl, C1-C6 alkoxy (optionally substituted by one or more halogen atoms), -S(O)nC1-C5 alkyl where n is 0,1 or 2, C1-C6alkylcarbonyl(amino), C1-C6 alkylcarbonyloxy, phenyl, benzyloxy, -NR R and a group of formula (Formula Removed) R and R each independently represent hydrogen or C1-C6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C1-C6 alkoxy; M represents a bond or -0-, -S-, -C=C-, -CH2O- or -OCH2(Scheme Removed) G3 represents an unsaturated 5- to 10-membered ring system which may camprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C1-C6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C2-C6 alkenyl, C1-C6 alkoxy (optionally substituted by one or more halogen atoms), -S(O)tC1-C6 alkyl where t is 0,1 or 2, C1-C6 alkylcarbonyl(amino), C1-C6 alkylcarbonyloxy, phenyl, benzyloxy and -NR11R12 and R11 and R12 each independently represent hydrogen or C1-C6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C1-C6 alkoxy. In the context of the present specification, unless otherwise stated, an alkyl, alkenyl or alkynyl substituent group or an alkyl moiety in a substituent group may be linear or branched. A haloalkyl or haloalkoxy substituent group will comprise at least one halogen atom, e.g. one, two, three or four halogen atoms. A hydroxyalkyl substituent may contain one or more hydroxyl groups but preferably contains one or two hydroxyl groups. When R1 and R 2, or R2 and R3 , form a ring, it should be understood that the ring may comprise up to one ring heteroatom only. In the definition of R , it should be noted that each of the saturated or unsaturated 3- to 10-membered ring system and the saturated or unsatturated 5- to 6-niembered ring may have alicyclic or aromatic properties. The same comment applies to the saturated or unsaturated 5- to 10-membered ring system in the definition of G2 . An unsaturated ring system will be partially or fully unsaturated. When L represents a C2-C6 alkyl or C2-C6 alkynyl group optionally interrupted or terminated by more than one moiety (e.g. two moieties) selected from O, NH, S, SO, SO2 and C(0), it may in some instances be possible for the two moieties to be adjacent to one another but otherwise the moieties will need to be separated by one or more carbon atoms. For example, whilst it is acceptable for C(0) or SO2 and NH to be adjacent to one another, combinations such as ISfH-NH, NH-O, 0-0, O-SO, O-SO2, SO-SO, SO2-SO2 and so on are undesirable. The person skilled in the art will know which moieties may be placed next to one another. In an embodiment of the invention, X represents an oxygen atom or a group NR4 where R4 represents hydrogen or C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl). In another embodiment of the invention, X represents NH or N-methyl. In a further embodiment, X represents NH. In one embodiment, Z1 and Z2 both represent an oxygen atom. In an embodiment of the invention, R1 represents hydrogen or a group selected from C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) select«i from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, cyano. carboxyl, -NR5 R6 , -CONR R , C1-C6. preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C1-C6, preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C1-C6, preferably C1-C4, alkylcarbonyl(oxy) (e.g. methylcarbonyl(oxy), ethylcarbonyl(oxy), n-propylcaTbonyl(oxy), isopropylcarbonyl(oxy), n-butylcarbonyl(oxy), n-p6ntylcarbonyl(oxy) or n-hexylcarbonyl(oxy)), -S(O)mC1-C6, preferably. C1-C4, alkeyl where m is 0,1 or 2 (e.g. methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, methylsulphonyl or ethylsulphonyl), C1-C6, preferably C1-C4, alkylsulphonylamino (e.g. methylsulphonylamino, ethylsulphonylamino, n-propylsulphonylamino, isopropylsulphaonylamino, n-butylsulphonylamino, n-pentylsulphonylamino or n-hexylsulphonylamino), C1-C6, preferably C1-C4, alkoxycarbonyl(amino) (e.g. methoxycarbonyl(amino), cthoxycarbonyl(amino), n-propoxycarbonyl(amino) or n-butoxycarbonyl(ainino)), benzyloxy and a saturated or unsaturated 5- to 6-membered ring which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring in turn being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, oxo, carboxyl, cyano, C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl orn-hexyl), C1-C6, {aeferably C1-C4, alkoxycarbony] (e.g. methoxycarbonyl or ethoxycarbonyl) and C1-C6, preferably C1-C4, hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH(OH)CH3); 2 R represents hydrogen or C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl); and 3 R represents hydrogen or C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Examples of saturated or unsaturated 3- to 10-membered ring systems that may be used, which may be monocyclic or polycyclic (e.g. bicyclic) in which the two or more rings are fused, include one or more (in any combination) of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicycIo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2,2.13hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofuranyl, tetrahydropyranyl, pyrazolyl, pyrazdnyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazmyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, jndolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl. Preferred ring systems include phenyl, pyridinyl and tetrahydropyranyl. Examples of saturated or unsaturated 5- to 6-membered ring substituents in R include cyclopentyl, cyclohexyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl. tetrahydropyranyl, thiomorpholinyl, pyrazolyl, pyrazinyl, pyridazinyl, thiazolidinyl, thienyl, isoxazolyl, pyrimidinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl and pyridinyl. Preferred rings include morphoUnyl, pyrimidinyl, phenyl, imidazolyl, piperidinyl, tetrahydropyranyl and triazolyl. Particular values for R1 include the following: (Formula Removed) In another embodiment of the invention, R represents hydrogen or a group selected from C1-C4 alkyl and a saturated or unsaturated 5- to l0-membered ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen, hydroxyl, cyano, carboxyl, -NR R , -CONR R , C1-C4 alkyl, C1-C4alkoxy, C1-C4 alkylcarbonyl(oxy), -S(0)niC1-C4 alkyl where m is 0, lor 2, C1-C4 alkylsulphonylamino, C1-C4 alkoxycarbonyl(amino), benzyloxy and a saturated or unsaturated 5- to 6-membered ring which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring in turn being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen, hydroxyl, 0x0, carboxyl, cyano, C1-C4 alkyl C1-C4alkoxycarbonyl and C1-C4 hydroxyalkyl; R2 represents hydrogen or C1-C4 alkyl; and R3 represents hydrogen or C1-C4 alkyl. In still another embodiment, R3 represents hydrogen or C1-C4 alkyl, particularly methyl; R2 represents hydrogen; and R3 represents hydrogen. Alternatively, R1 and R2 may together with the carbon atoms to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur (e.g. cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, 3 tetrahydrofuranyl or terahydrotbiophenyl), and R is as previously defined. As a further alternative, R2 and R may together with the carbon atom to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur (e.g. cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydrothiophenyl), and R is as previously defined. R5 ,R6 ,R7 and R8 eachindependently represent hydrogen or C1-C6, preferably Ci-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents ind^ndently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C1-C6 preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy). In an embodiment of the invention, R5 , R6 , R7 and R8each independently represent hydrogen or C1-C6, preferably C1-C4, alkyl. In-another embodiment, R , R , R and R each independently represent hydrogen. L represents -CH2C(0)- or -C(0)CH.2-, or L represents a C2-C6, preferably C2-C4, alkyl or C2C6preferably C2-C4, allcynyl group optimally interrupted or terminated by at least one moiety (e.g. one or two moieties independently) selected from O, NH, S, SO, SO2 and C(0) (for example, -(CH2)2-. -(CH2)3-, -(CH2)4-. -(CH2)5-, -(CHz)^-, -OC-. -CH2-OC-. -CsC-CHα-, -0-(CH2)3-NH-. -NH-(CH2)3-0-, -CH(CH3)-, -(CH2)2-C(0)-. -C(0)-(CH2)2-. -CH2CH(CH3)-, -CH(CH3)CH2-, -(CH2)2-0-CH2- or -CH2-0-(CH2)2). or L represents a C3-C6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), methylC3-C6 cycloalkyl (e.g. methylcyclopropyl) or C3-C6 cycloalkylmethyl (e.g. cyclopropylmethyl) group, each of the recited groups being optionally substituted with at least one substituent (e.g, one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine), C1-C4, preferably C1-C2, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl), C1-C4, preferably C1-C2, haloalkyl (e.g. trifluoromethyl or pentafluoroethyl), C1-C4, preferably C1-C2, alkoxy (e.g. methoxy or ethoxy) and C1-C4, preferably C1-C2, haloalkoxy (e.g. trifluoromethoxy) (such as -CH20CH(R)CH2NH- or -hfHCH2CH(k)OCH2- where R represents methyl, hydroxylorraethoxy, -CH(CH3)-CH(OH)-, -CH(0H)-CH(CH3)-, -CH2CH(QH)-, -CH(OH)CH2-, -CH2CH(OCH3)- or -CH(OCH3)CH2-), or L represents a C3-C4 all^lene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G2 to form a ring (for example, if G2 represents an unsubstituted phenyl group and L represents a C3 alkylene chain, G and L together form a 2,3-dihydroinden-2-yl group havmg the structure: (Strecture Removed) In an embodiment of the invention, reading from left to right in formula (I), L represents -C(0)CH2-, or L represents C2-C4 alkyl optionally intermpted or terminated by an oxygen atom, cyclopropyl or cyclopropylmethyl, each of which is optionally substituted with one or two substituents independently selected from hydroxyl, halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy, or L represents a C3-C4 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to lO-membered ring system of G2 to form a ring. In a further embodiment of the invention, L represents (readmg from left to right in formula (I)) -C(0)CH2-. -(CH2)2-, -CH(CH3)-, -CH(CH3)CH2-. -CH(0H)-CH(CH3)-, -CH(0H)CH2-. -CH(OCH3)CH2-, -CH2-0-(CH2)2. cyclopropyl, cyclopropylimethyl, or L represents a C3 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to l0-memered ring system of G2 to form a ring. G2represents a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the nng system being optionally substituted withat least one substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, cyano, nitro, C1-C6,, preferably C1-C4, alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl (optionally substituted by one or more, e.g. one, two or three, substituents independently selected from cyano, halogen such as chlorine, fluonne, bromine or iodine, hydroxyl and methoxy), C2-C6, preferably C2-C4, alkenyl (e.g. ethenyl, prop-l-enyl, prop-2-enyl, but-1-enyl, pent-1-enyl, hex-1-enyl or 2-methyl-pent-2-enyl), C1-C6, preferably C1-C4, alkoxy such as methoxy, ethoxy, n-propoxy or n-butoxy (optionally substituted by one or more, e.g. one, two or three, halogen atoms such as chlorine, fluorine, bromine or iodine), -S(O)nCi-Cg, preferably C1-C6, alkyl where n is 0,1 or 2 (e.g. methylthio, ethyithio, methylsulphinyl, ethylsulphinyl, methylsulphonyl or ethylsulphonyl), C1-C6, preferably C1-C4, alkylcarbonyl(amino) (e.g. methylcarbonyl(amino), ethylcarbonyl(anuno), n-propylcarbonyl(amino), isopropylcarbonyl(amino), n-butylcarbonyl(ainino), n-pentylcarbonyl(amino) or n-hexylcarbonyl(an3ino)), C1-C6, preferably C1-C4, alkylcarbonyloxy (e.g. methylcarbonyloxy, etbylcaitonyioxy, n-propylcarbonyloxy, isopropylcarbonyloxy, n-butylcarbonyloxy, n-pentylcarbonyloxy or n-hexylcarbonyloxy), phenyl, benzyloxy, -NR9 R10 and a group of formula (Formula Removed) Examples of saturated or unsaturated 5- to 10-membered ring systems that may be used in 2 G , which may be monocyclic or polycyclic (e.g. bicyciic) in which the two or more rings are fused, include one or more (in any combination) of cyclopentyi, cyclohexyl, bicyclo[2.2.1]heptyI, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholmyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yI, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydroben2ofiiranyl, tetrahydropyranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, diicnyl, isoxazolyh pyridazinyl, thiadiazolyl, pyrrolyi, furanyl, thiazolyl. indolyl, imidazolyl, pyrimidinyl. benzimidazolyl, triazolyl, tetrazolyl and pyridinyl. Preferred ring systems include phenyl, indolyl, thienyl and piperidinyl. R9 and R10 each independently represent hydrogen or C1-C6 preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C1-C6 preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy). In an embodiment of the invention, G represents a saturated or unsaturated 5- to 9- membered ring system which may comprise one ring heteroatom selected from aitrogen, oxygen and sulphur, the ring system being optionally substituted with one or two substituents independently selected from halogen, hydroxyl, cyano, nitro, C1-C4 alkyl (optionally substituted by one or more, e.g. one, two or three, substituents indepenttently selected from cyano, halogen such as chlorine, fluorine, bromine or iodine, hydroxyl and methoxy), C2-C4 alkenyl, C1-C4 alkoxy (optionally substituted by one or more, e.g. one, two or three, halogen atoms such as chlorine, fluorine, bromine or iodine), -S(0)nC1-C4 alkyl where n is 0,1 or 2, C1-C4 alkylcarbonyl(ammo), 9 10 C1-C4 alkylcarbonyloxy, phenyl, benzyloxy, -NR R and a group of formula (Formula Removed) In another embodiment. G represents a saturted or unsaturated 5- to 9-membered ring system which may cominise one ring heteroatom selected from nitrogen and sulphur (e.g. phenyl, indolyl, thienyl or piperidinyl), the ring system being optionally substituted with one or two substituents independently selected from halogen, C1-C4 alkyl and a group of formula (Formula Removed) In an embodiment of the invention, M represents a bond, -O- or -CsC-. In a further embodiment, M represents a bond. G represents an unsaturated 5- to 10-membered ring system which may comprise at least one ring faeteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) seiectsed from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, cyano, nitro, C1-C6 preferably C1-C4 alkyl such as methyl, ethyl, n-propyl, isppropyl, n-butyl, isobutyi, tert-butyl, n-pentyl or n-hexyl (optionally substituted by one or more, e.g. one, two or three, substituents independently selected from cyano, halogen such as chlorine, fluorine, bromine or iodine, hydroxyl and methoxy), C2-C6, preferably C2-C4, alkenyl (e.g. ethenyl, prop-1-enyI, prop-2-enyl, but-1-enyl, pent-1-enyl, hex-1-enyl or 2-methyI-pent-2-enyl), C1-C6, preferably C1-C4, alkoxy such as methoxy, ethoxy, n-propoxy or n-butoxy (optionally substituted by one or more, e.g. one, two or three, halogen atoms such as chlorine, fluorine, bromine or iodine), -S(O)tC1-C6, preferably C1-C4, alkyl where t is 0,1 CM: 2 (e.g. methylthio, ethylthio, methylsulphinyl, ethylsuiphinyl, methylsulphonyl or ethylsulphonyl),C1-C6, preferably C1-C4, alkylcarbonyl(amino) (e.g. methylcarbonyl(amino), ethylcarbonyl(ammo), n-propylcarbonyl(amino), isopropylcarbonyl(amino), n-butylcarbonyl(amino), n-pentylcarbonyl(amino) or n-hexylcarbonyl(amino)), C1-C6, preferably C1-C4, alkylcarbonyloxy (e.g. methylcarbonyloxy, ethylcarbonyloxy, n-propylcarbonyloxy, isopropylcarbonyloxy, n-butylcarbonyloxy, n-pentylcarbonyloxy or n-hexylcarbonyloxy), phenyl, benzyloxy and -NR1212. Examples of unsaturated 5- to 10-membered ring systems that may be used in G , which may be monocyclic or polycyclic (e.g. bicyclic) in which the two or more rings are fused, include one or more (in any combination) of cyclopentenyl, cyclohexenyl, phenyl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3- dihydrobenzofuranyl, pyrazolyl, pyrazinyl, thjazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl. Preferred ring systems include phenyl, thienyl, naphthyl, benzofuranyl, benzothienyl, pyridinyl, pyrrolyl, furanyl, benzodioxolyl, quinolinyl and 2,3-dibydrobenzofuranyl. R11 and R12 each independently represent hydrogen or C1-C6, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C1-C6, preferably C1-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy). In one embodiment, G represents an unsaturated 5- to 10-membered ring system which may comprise one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (e.g. phenyl, thienyl, naphthyl, benzofuranyl, benzothienyl, pyridinyl, pyrrolyl, furanyl, benzodioxolyl, qumolinyl and 2,3-dihydrobenzofuranyl), the ring system being optionally substituted with one or two substituents independently selected from halogen, hydroxyl, cyano, nitro, C1-C4alkyl(optionallysubstitutedby oneormore, e.g. one, two or three, substituents independently selected from cyano, halogen such as chlorine, fluorine, bromine or iodine, hydroxyl and methoxy), C2-C4 alkenyl, C1-C4 allcoxy (optionally substituted by one or more, e.g. one, two or three, halogen atoms such as chlorine, fluorine, bromine or iodine), -S(0)t C1-C4 alkyl where t is 0,1 or 2, C1-C4alkylcarbonyl(amino), C1-C4 alkylcarbonyloxy, phenyl, benzyloxy and In another embodiment, G3 represents an unsaturated 5- to 10-membered nng system which may comprise one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (e.g. phenyl, thienyl, naphthyl, benzofuranyl, benzothienyl, pyridinyl, pyrrolyl, furanyl, brazodioxolyl, quinolinyl and 2,3-dihydrobenzofuranyl), the ring system being optionally substituted with one or two substituents independently selected from halogen, cyano, nitro, C1-C4 alkyl (optionally substituted by one or more, e.g. one, two or three, substituents independently selected from cyano and halogen), C1-C4 alkoxy (optionally substituted by one or more, e.g. one, two or three, halogen atoms), C1-C4 alkylthio, C1-C4 alkylcarbonyl(amino), phenyl and benzyloxy. In still another embodiment, G3 represents an unsaturated 5- to 10-membered ring system which may comprise one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (e.g. phenyl, thienyl, naphthyl, benzofuranyl, benzothienyl, pyridinyl, pyrrolyl, furanyl, benzodioxolyl, quinolinyl and 2,3-dihydrobenzofuranyl), the ring system being optionally substiututed with one or two substituents independently selected from fluorine, chlorine, cyano, nitro, methyl, cyanomethyl, trifluoromethyl, methoxy, trifluoromethoxy, methylthio, methylcarbonyl (acetyl), methylcarbonylamino (acetylamino), phenyl and benzyloxy. Particular values for G2 include the following: (Structure Removed) In an embodiment of the invention: X represents -NH- or -N(CH3)-; Y represents NH; Z1 and Z2 both represent an oxygen atom; R represents hydrogen or methyl; R2 represents hydrogen; R represents hydrogen; L represents -C(0)CH2-. -(CHah". -CRiCHsh -CH(CH3)CH2-, -CH(0H)-CH(CH3)-. -CH(0H)CH2-, -CH(OCH3)CH2-. -CH2-0-(CH2)2. cyclopropyl, cyclopropylmethyl, or L represents a C3 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 9-membered ring system of G to form a ring; G represents represents a saturated or unsaturated 5- to 9-membered nng system which may comprise one ring heteroatom selected from nitrogen and sulphur, the ring system being optionally substituted with one or two substituents independently selected from halogen, C1-C4 alkyl and a group of formula (Formula Removed) M represents a bond, -0- or -C=C-; and 3 G represents an unsaturated 5- to 10-membered ring system which may comprise one or two ring heteroatoms independently selected from nitrogen, oxygen and sulf hur, the ring system being optionally substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro, methyl, cyanomethyl, trifluoromethyl, methoxy, trifluoromethoxy, methylthio, methylcarbonyl, methylcarbonylamtao, phenyl and benzyloxy. Examples of compounds of the invention include: 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-biphenyl-4-yl)-ethyl]-acctamide, N-[2-(4'-Cyano-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoinudazolidin-4-yl)-N-(2-phenyI-cyclopropyl)-acetamide, N-[2-(4-Chloropheyl)ethyl]-2-{2,5-dioxoimidazolidin-4-yl)-acetamide, N--(2-Biphenyl-4-yl-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-DioXoimidazoIidin-4-yl)-N'-[2-(7-m6thyl-lH-indol-3-yl)ethyl]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yI)-N-[2-(4-phenoxyphenyl)ethyl3-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-fluorophenyl)ethyl]-acetamide, N-[2-(4-Bromophenyl)ethyl]-2-(2,5-dioxoimdazolidin-4-y])-acetamide, ;V-{2-(2,4-Dichlorophenyl)ethyl3-2-(2,5-dioxoinudazolidin-4-yl)-acetaniide, N-[2-(3'-Chloro-bipbenyl-4-yl)-ethy]]-2-(2,5-dioxoiinida2olidin-4-yl)-acetamide, N-[2-(4'-Benzyloxy-biphenyl-4-yl)-ethyl3-2-(2,5-dioxoiimdazoUdin-4-yl)-acetamide, 2-(2,5-Dioxoinudazolidin-4-yl)-N-[2-(4-thiophen-3-yl-phenyl)ethyl]-acetamide, 2-(2,5-dioxoimidazolidin-4-yl)-N-[2-(4-thiophen-2-yl-phenyl)ethyl]-acetaimde, /V-[2-(4'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamidc, 2-(2,5-dioxoimidazolidin-4-yl)-yV-[2-(4'-raethylsulfanyl-biphenyl-4-yl)ethyl]-acetamide, 2-(2,5-Dioxoinuda2olidin-4-yl)-A^-[2-(3'-nitro-biphenyl-4-yl)ethyl]-acetainide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methyl-biphenyl-4-yl)ethyl3-acetamide, A'-[2-(3-Acetylamino-biphenyl-4-yl)ethyl]-2-(2,5-dioxoiimda2oHdin-4-yl)-acetainide, 2-(2,5-dioxoimidazoLIdIN-4-yl)-M-[2-(4-naphthalen-2-yl-phenyl)ethyl]-acelamide, N-[2-(3'^'-DichlorcKbiphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-aoetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-methyl-biphenyl-4-yl)ethyl]-acetaBudc, N-[2-(4-Benzofuran-2-yl-phenyl)ethyl3-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimida2olidin-4-yl)-N-[2-(3'-methoxy-biphenyl-4-yl)ethyl]-acetaniide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-[l, r;4', r']terphenyl-4-ylethyl)-acetarmde, N-[2-(4'-Acetyl-biphenyl-4-yl)ethyl3-2-(2,5-dioxoinudazolidin-4-yl)-acetanMde, N-[2-(4-Benzo[b]thiophen-2-yl-phenyl)ethyl]-2-(2,5-dioxoimdazolidin-4-yl)-acetamide, N-[2-(4'-Cyanomethyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acctamide, 2-(2,5-Dioxoimidazolidm-4-yl)-N-[2-(4-pyridin-3-yl-phenyl)ethyl]-acetamide. 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(lH-pyrrol-2-yl)phenyl3ethyl)-acetaraide, 2 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-furan-2-yl-phenyl)ethyl]-acetamide, 2-(2,5-Dioxoimida2olidin-4-yl)-N-(2-thiophen-2-yl-ethyl)-acetainide, N-[2-(4-tert-Butylphenyl)ethyl]-2-(2.5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(4-Chloropheny])-l-methylethyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide, -{[l-(4-Chlorophenyl)cyclopropyl]methyl}-2-(2,5-dioxoimdazolidin-4-yl)acetamidc, N-2,3-Dihydro-lH-inden-2-yl-2-(2,5-dioxoimdazolidin-4-yl)acetamide, N-[2-(4-Chloiophenyl)ethyl]-2 ^-[2-(4-Huoro-1,1 '-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoiniidazolidm-4-yl)acetaraide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-1,1 '-biphenyl-4-yl)propyl]-acetamide, -[(15,2R)-2-(4'-MethoxybiphenyM-yl)cyclopropyI]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetaniide, iV^[(15,2R)-2-(4-Cyanobiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoiinidazolidin-4-yl)-acetaimde, N-[(15.2R)-2-(4'-Acetylbiphcnyl-4-yl)cyclopropylj-2-(4-methyl-2,5-dioxoiraidazolidin-4-yl)-acetamide, N-{(15,2R)-2-[4'-(Acetylamino)biphenyl-4-yl]cyclopropyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(4'-Cyanobiphenyl-4-yl)propyl3-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimida2olidin-4-yl)-N-[2-(3'-methoxybiphenyl-4-yl)eliiyl]-acetaraide, N-[2K4'-CyanoO'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazoIidin-4-yl)-acetatnide, 2-(2,5-dioxoimidazolidin-4-yl)-N-methyl-N-(2-phenylethyl)-acetanude, N-[l-(4-Cfalorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetarnide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-hydroxy-l-raethyl-2-phenylethyl)-acetainide, N-{2-[4-(l,3-Benzodioxol-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-DioxoimidazoIidin-4-y])-N-[2-(3'-methoxybiphenyl-4-yl)propyl]-acctamide, N- {2-[3'-(Acetylamino)biphenyl-4-y]]propyl) -2-(2,5-dioxoimidazolidin-4-yl)- acetamide, N-[2-(3'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazo]idin-4-yl)-acetamide, N-{2-(4'-Acetylbiphenyl-4-yl)propyI]-2-(2,5-dioxoinudazolidm-4-yl)-acetainide, N-{2-[4-(l-Benzotbicn-2-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)- acetamide, N-[2-(3'-CyanobiphcnyI-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acctainide, N-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-dioxoimidazolidin-4-yl)-N--[2-(4'-fluoro-3'-methylbiphenyl-4-yl)propyl]- acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-- {2-[3 '-(methylthio)biphenyl-4-yl]propyl }- acetamide, 2-(2,5-DioxoimidazoJidin-4-yl)-N--{2-[4-(6-methoxypyridin-3-yl)phenyl]propyl)- acetanude, 2-(2,5-Dioxoiniidazo]idin-4-yl)-N-[2-(4'-methoxy-3'-methylbiphenyl-4-yl)propyl]-acetamide, N- {2-[4-(2,3-Dihydro-1 -benzofuran-5-yl)phenyl]propyl} -2-(2,5-dioxoimidazolidin-4-yl)-acetamid6, 2-(2,5-Dioxoimldazolidin-4-yl)-N-{2-[3'-(trifluoroniethoxy)biphenyl-4-yl]propyl}-acetamide, N-[2-(3',4'-Dimethoxybiphenyl-4-y])propyl]-2-(2,5-dioxoimidazoJidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-qiunoIin-3-ylphenyl)propyl]-acetamide. N-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(1,3-BenzodioxoI-5-yl)-2,3-dihydro-lH-inden-2-yI3-2-(2,5-dioxoimidazolidin-4-yl)-acetanude, 2-(2,5-Dxoxoimidazo]idin-4-yl)-N-[5-(3-methoxypheny])-2,3-dihydro-lH-inden-2-y]]-acetamide. N-{5-[3-(Acetylamino)pheny]]-2,3-dihydro-lH-inden-2-yl}-2-(2,5-dioxoimidazolidm- 4-yl)-acetanude, N[5-(3-Acetylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamide, N-[5-(4-Acetylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamide, N-[5-(l-Benzothien-2-yl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamide, N-[5-(3-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamide, N-[5-(4-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamlde, 2-(2,5-Dioxoiimdazolidin-4-yl)-N-[5-(4-fluoro-3-methylphenyl)-2,3-dihydro-lH-inden-2-yl]-acetaniide, 2-(2,5-Dioxoiimdazolidin-4-yl)-N-{5-[3-(methylthio)phenyl]-2.3-dihydro-lH-inden-2-yl}-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-(6-methoxypyridin-3-yl)-2,3-dihydro-lH-inden-2-yl]-acetamide, 2 N-[5-(2,3-Dihydro-l-benzofuran-5-yl)-2,3-dihydro-lH-inden-2-yl]-2-(2^-dioxoimidazoiidin-4-yl)acetamide, N-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(4'-Huorobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-icetamide, N-{2-[4-(l,3-Benzodioxol-5-y])phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-I)-acetamide, N-[2-(3'-Mothoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide, N-(2-[4-(l-Benzothien-2-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide, N-[2-(3'-Cyanobiphenyl-4-yl)propyI]-2-(4-methyl-2,5-dioxoimidazoIidm-4-yl)- acetamide, N-[2-(4'-Fluoro-3'-naethylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4- y])-acetamide, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N- {2-[3 '-(methylthio)biphenyl-4-yl]propyl) -acetamide, N-{2-[4-(6-Methoxypyridin-3-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetatnide, N-[2-(4'-Methoxy-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimida2olidin-4-yl)-acetamide, N-{2-[4-(2,3-Dihydro-l-benzofuran-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoinudazolidin-4-y])-acetanude, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl) -acetamide, N-[2-(3,4'-Dimethoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide, N-[5-(4-Fluorophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxotmidazolidin-4-yl)-acetamide, N'-[5-(l,3-BenzodioxoI-5-yl)-2.3-dihydro-lH-inden-2-yl3-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(3-Methoxyphenyl)-2,3-dihydro-lH-inden-2-y]]-2-(4-methyl-2.5-dioxoiraidazolidin-4-y])-acetamide. N-{5-[3-(Ac6tylamino)phenyl]-2,3-dihydro-lH-inclen-2-yl}-2-(4-methyl-2,5-dioxoinudazoIidin-4-yl)-ac6tamide, N-[5-(3-Acetylphenyl)-2,3-dihydro-lH-inden-2-yI]-2-(4-methyl-2,5-dioxoimidazoIidin-4-yl)-acetamide, N-[5-(4-Acetylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(l-Benzothien-2-yl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2.5-dioxoinudazolidin-4-yl)-acetamide, N-[5-(3-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(4-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-ac6tamide, N-[5-(4-Fluoro-3-niethylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetainide, 2-(4-Methyl-2^-dioxoimidazolidin-4-yl)-N-{5-[3-(methylthio)phe!nyI]-2,3-dihydro-lH-inden-2-yl }-acetamide, A^-[5-(6-Methoxypyridin-3-y])-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2.5-dioxoinudazolidin-4-yl)-acetamide, N-[5-(4-Methoxy-3-methylphenyl)-2,3-dihydro-lH-indcn-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N:-[5-(2,3-Dihydro-l-benzoftiran-5-yl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-{4-Methyl-2,5-dioxoimidazo]idin-4-yl)-N-{5-[3-(trifluoromethoxy)phenyl]-2,3-dihydro- lH-indcn-2-yl} -acetamide, N-[5-(3.4-Dinaethoxyphenyl)-2,3-dihydro-lH-inden-2-yl3-2-(4-methy]-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(4-Cyano-3-methylphenyl)-2,3-dihydro-lH-inden-2-yl].2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimida2olidin-4-yl)-N-(2-{4-[4(trifluoromethyl)phenoxy]phenyl}etbyl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N- {2-[4-(4-methoxyphenoxy)phenyl]ethyl} -acetamide, 2-(2,5-dioxoimdazolidin-4-yl)-N-(2-{4-[4-(trifluoromethoxy)phenoxy]phenyl}ethyl)-acetamide, N- [ 2-[4-(4.Chlorophenoxy)phenyl]ethyl) -2-(2,5-dioxoimidazolidin-4-yl)-acetainide, N- {2-[4-(4-Acetylphenoxy)phenyl] ethyl} -2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimida2olidin-4-yl)"N-{2-[4-(pyridin-3-yloxy)phenyl]ethyl}-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-7/-(2-{4-[(6-methoxypyridin-3-yl)oxy]phenyl}ethyl)- acetamide, N- {2-[4-(4-Cyanoph6noxy)phenyl]ethyl} -2-(2,5-dioxoimidazolidin-4-yl)-acetanude, 2-(2,5-dioxoimidazolidin-4-yl)-N-{ 2-[4-(4-methylphenoxy)phenyl]ethyl} -acetamide, 2-(2,5-DioxoinudazoUdin-4-yl)-N-{2-[4-(4-fluorophenoxy)phenyl3ethyl}-acetamide, N-(2-Biphenyl-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimidazoiidin-4-yl)-acetaraide, N-[2-{ 1,1 '-Bipheny]-4-yl)-2-inethoxyethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetanude, N-[2-(l,r-Biphenyl-4-yl)-ethyl3-2-(2,5-dioxoimidazolidin-4-yl)-N-methylacetamide, 2-(2,5-dioxoimidazolidin-4-yl)-N-[2-(4-phenylethynyl-piperidin-l-yl)ethyl]- acetamide, N-{2-[(4-Bromobenzyl)oxy]ethyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-( 1,1 '-Biphenyl-4-yl)-2-oxoethyl (2,5-dioxoimidazoIidin-4-yl) acetate, and pharaiaceutically acceptable salts and solvates thereof. It will be appreciated that the particular substituents and number of substituents in tiie compounds of the invention are selected so as to avoid sterically undesirable combinations. Each exemplified compound represents a particular and independent aspect of the invention. It will be appreciated that the compounds according to the invention may contain one or more asymmetrically substituted carbon atoms. The presence of one or more of these asymmetric centres (chiral centres) in compounds according to the invention can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof. Racemates may be separated into individual optically active forms using known procedures (cf. Advanced Organic Chemistry: 3rd Edition: author J March, pl04-107) including for example the formation of diastereomeric derivatives having convenient optically active auxiliary species followed by separation and then cleavage of the auxiliary species. Where optically active centres exist in the compounds of the invention, we disclose all individual optically active forms and combinations of these as individual specific embodiments of the invention, as well as their corresponding racemates. Where tautomers exist in the compounds of the invention, we disclose all individual tautomeric forms and combinations of these as individual specific embodiments of the invention. The compounds of the invention may be provided as pharmaceutically acceptable salts or solvates. These include acid addition salts such as hydrochloride, hydrobromide, citrate, tosylate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine. Examples of solvates include hydrates. The compounds of formula (I) have activity as pharmaceuticals. As previously outlined the compounds of the invention are metalloproteinase inhibitors, in particular they are inhibitors of MMP12 and may be used in the treatment of diseases or conditions mediated compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined. The invention also provides a method of treating an obstructive airways disease (e.g. asthma or COPD) which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined. For the above-mentioned dierapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (])/salt/solvate (active ingredient) may be in the range from 0.001 mg/kg to 75 mg/kg, in particular from 0.5 mg/kg to 30 mg/kg. This daily dose may be given in divided doses as necessary. Typically unit dosage forms will contain about 1 mg to 500 mg of a conrpound of this invention. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingr«lient) is in association with a pbarmaceutically acceptable adjuvant, diluent or carder. Dependmg on the mode of administration, the pharmaceutical composition wiH preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by wdght being based on total composition. The compositions are not mere admixtures but have synergistic properties. Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined. The invention also provides a method of treating an obstructive airways disease (e,g. asthma or COPD) which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined. For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I)/salt/solve (active ingredient) may be in the range from 0.001 mg/kg to 75 mg/kg, in particular from 0.5 mg/kg to 30 mg/kg. This daily dose may be given in divided doses as necessary. Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in associated on with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition. Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I) ox a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier. The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier. The pharmaceutical compositions of this invention may be administered in standard manner for the disease or condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal adminstration or by inhalation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for-parenteral use (including intravenous, mtramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions. In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequratially) with, one or more pharmacological agents of value in treating one or more diseases or conditions referred to hereinabove such as "Symbicort" (trade mark) product. Preparation of the compounds of the invention The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined above which comprises, (a) when X represents an oxygen atom or a group NR4 , reacting a compound of formula (Formula Removed) wherein X represents an oxygen atom or a group NR and L, G and R are as defined in formula (I), with an activatedcarboxylic acid of formula (Formula Removed) wherein Y, Z , Z , R , R and R are as defined in formula (I); or (b) when X represents CH2, reacting an activated carboxylic acid of formula (IV) as defined in (a) above with methoxymethylamine or a salt thereof (e.g. hydrochloride salt) followed by reaction with a Grignard reagent of formula 2 (Formula Removed) wherein Hal represents a halogen atom such as chlorine or bromine and L and G are as defined in formula (I); or (c) when X represents CH2, reacting a compound of formula (Formula Removed) wherein Y, Z , Z , R , R and R are as defined in formula (3), with a compound of formula (Formula Removed) wherein LG represents a leaving group such as halogen or sulphonate (e.g. methylsulphonate or toluenesulphonate) and L and G are as defined in formula (I), in the presence of a strong base (e.g. sodium hydride or lithium diisopropylamide); and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate. In process (a), the reaction between the compounds of formulae (III) and (IV) represents a simple amide or ester coupling well known to those skilled in the art. The carboxylic acid of formula (IV) must be activated in some way, for example as the acid halide, anhydride, acyl urea or acyl derivative of N-hydroxysuccinimide. For a general description of the preparation of amides and esters see, for example, Carey, F,A. and Sundberg, J., Advanced Organic Chemistry, 3rd Edition, pp 144-152,1990. It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of the invention may involve, at various stages, the addition and removal of one or more protecting groups. The protection and deprotection of functional groups is described in Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Syndesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999). Compounds of formulae (III), (IV), (V), (VI) and (VD) are either commercially available, are known in the literature or may be prepared using known techniques. For example, compounds of formula (IV) in which R represents a hydrogen atom, Y represents NH and Z1 and Z2 both represent oxygen may be prepared acceding to the reaction scheme below: (Scheme Removed) Intermediate 1 Alternatively, compounds of fonnula (IV) in which R represents a hydrogen atom, Y represents NH, Z represents sulphur and Z represent oxygen may be prepared by reacting Intermediate 1 above with thiocarbamic acid (H2N-C(S)-0H) and sodium cyanide in the presence of a solvent mixture of ethanol and water, e.g. as described in /. Chem. Soc, 1959, page 396. Other methods are available for preparing compounds of formula (IV). For example, a wide range of α-amino acids are useful as synthons to dioxo-imidazolidines and oxo-thioxo-imidazolidines. It is well known that salts of cyanic acid, urea, or thiocyanic acid together with an ammonium salt react with α-amino acids to form these heterocycles (Anteunis, M.J,0.; Spiessens, L.; Witte, M. De; Callens, R.; Reyniers, Bull Soc. Chim. Belg.. EN, 96, 6,1987,459-466; Dakin; Am. Chem. J., 44,1910,49; Haurowitz et al., J. Biol. Chem., 224,1957). Several suitable dioxo-imidazolidine and oxo-thioxo-imidazolidine acids are commercially available or are described in the literature as indicated below (unless otherwise stated, the numbers in brackets are CAS registry numbers); (2,5-Dioxo-imidazolidin-4-y})-acetic acid (5427-26-9, 26184-52-1. 26184-53-2, 67337-71-7); (3-Methyl-2,5-dioxo-imidazolidin-4-yl)-acetic acid (26972-46-3); 5-Oxo-2-thioxo-imidazolidin-4-yl)-acetic acid (41679-36-1. 61160-00-7); (2,5-Dioxo-4-phenyl-imidazolidin-4-yl)-acetic acid (62985-01-7); (4-Methyl-2,5-dioxo-imidazolidin-4-yl)-acetic acid (beilstein registry number 145446); 4-Imidazolidineacetic acid, 4-(hydroxym6thyl)-2,5-dioxo-, (4R)- (90) (391870-39-6): 4-Imidazolidineacetic acid, 4-(4-chlorophenyl)-2,5-dioxo- (9Cr) (250352-11-5); 4-lmidazoiidineacetic acid, a-methyl-2,5-dioxo- (9C3) (184681-52-5); l,3-Diazaspiro[4.4]nonane-6-carboxylic acid, 2,4-dioxo-, cis- (9CI) (147676-21-9); l,3-Diazaspiro[4.5]decane-6-carboxyiic acid, 2,4-dioxo- (7CI, SCI) (947-10-4); l,3-Diazaspiro[4.43nonane-6-carboxylic acid, 2-oxo-4-thioxo- (9CI) (197315-95-0); 4-Imidazolidineacetic acid, 5-oxo-2-thioxo- (9CI) (41679-36-1); 4,4-Imidazolidinediacetic acid, 2,5-dioxo-(8CI, 9C15 (5624-17-9); and 4-ImidazoIidineacetic acid, 4-hydroxy-2,5-dioxo- (9CI) (78703-76-1). The present invention will now be further explained by reference to the following illustrative examples. 1HNMR and 13CNMR were recorded on a Varian Inova 400 MHz or a Varian Mercury-VX 300 MHz instrument. The central peaks of chloroform-d (δH 7.27ppm), dimethylsulfoxide-d6 (δH 2.50 ppm) or methanol-d4 (δH 3.31 ppm) where used as internal references. Low-resolution mass spectra were obtained on an Agilent 100 LC-MS system equipped with an APCI ionisation chamber. Column chromatography was carreed out using silica gel (0.063-02 mm) (Merck). Unless stated otherwise, starting materials were commercially available. All solvents and commercial reagents were laboratory grade and used as received. Abbreviations: NMP: l-methyl-2-pyrollidinone THA: trifluoroacetic acid HOBT: l-hydroxybenzotriazole (Table Removed) I. Preparation of non-commercial amines (Formula Removed) 2-(4-Bromo-phenyl)-ethylamine (2mmoI, 400mg) was dissolved in 4mL THF (dry, mol sieves) and di-tert-butyl dicarbonate (1.2eq 2.4mmoI 520mg) was added slowly. The reaction mixture was stirred in room temperature for 1 hour before it was diluted with l00mL ethyl acetate and washed with l00mL sat. NaHCO3/aq. The organic phase was dried over Na2S04, filtrated and evaporated to dryness. The BOC-protected amaie was dissolved in a mixture of 10mL toluene, 2.5mL ethanol and 2.5mL 2M Na2CO3/aq. PdCla(dppf) (0.03eq, 50mg) was added together with a corresponding boronic acid (1.05eq, 2.1mmol). The siolution was degassed with nitrogen and the vessel was sealed before it was stirred overnight at 80°C. The reaction mixture was diluted with 50mL toluene and 50mL water. After mixing, the organic layer was transferred directly on to a silica column and purified by chromatography (toluene- ethylacetate). To remove the protecting group the compound was stirred in a mixture of 5mL cone. HCl in l0mL THF for 30 min. The solution was neutralised with IM NaOH/aq and extracted with dichloromethane (2x). The combined organic layers was dried over Na2SO4, filtrated and evaporated to dryness. The amines were used in the amide synthesis without any further purificadon. II. Coupling of amines to 5 hydantoin acetic acid:- amide synthesis (Formula Removed) R2 600µL of a 0.15M solution in NMP of 5-hydantoin acetic acid was mixed with 98mg of polystyrene-bound carbodiimide resin (loading I.28mmol/g). 340µL of a 0.3M solution of HOST in NMP was added to the mixture and vortexed for 10 minutes before 20µL of a 0.3M solution in NMP of the corresponding amine was added. The reaction mixtures were vortexed overnight at room temperature in sealed vessels. Resin was removed by filtration and the solution was evaporated to dryness. The products were purified on semiprep-HPLC C18-column (H2O:CH3CN, 0.1% TFA buffer, gradient 10% to 95% CH3CN, 10 min). The following 2-(2,5-Dioxo-unidazolidin-4-yl)-acetamides were prepared according to the general procedure A outlined above. Example 1 2-(2,5.Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-biphenyl-4-yl)-ethyl]-acetamide 1H NMR (400MHZ,DMSO-D6): δ 10.56 (IH, s); 8.07 (IH, t); 7.71-.7.65 (2H, m); 7.59-.7.55 (2H, m); 7.32-.7.24 (4H, m); 4.23-4.19 (IH. m); 3.35-3.26 (2H, m); 2.75 (2H. t) 2.56-2.37(2H, m) APCI-MS m/z: 356.4 [MH+] Example 2 N-[2-(4'-Cyano-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide 1H NMR (400MHz,DMSO-d6): δ10.56 (IH, s); 8.07 (IH, t); 7.92-.7.84 (4H, m); 7.79 (IH, s); 7.69 (2H, d); 7.35 (2H, d); 4.21(1H. t); 3.37-3.27 (2H. m); 2.78 (2H, t) 2.57-2.36(2H, m) APC1-MS m/z: 363.4 [MH+] Example 3 2-(2,5-Dioxoumdazolidin-4-yl)-N-(2-phenyl-cyclopropyl)-acetamide APCIMS m/z: 274.3 [MH+] Example 4 N'[2-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimdazolidin-4-yl)-acetamide APC1-MS m/z: 296.3 [MH+] Example 5 N-(2-Biphenyl-4-yl-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APC1-MS tn/z: 338.4 [MH+] Example 6 2-(2,5-Dioxoimidazolidin-4-yl)-N.[2-(7-methyl-lH-indol-3-yl)ethyl]-acetamide APCIMS m/z: 315.3 [MH+] Example 7 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-phenoxyphenyl)ethyl]-acetamide APC1-MS m/z: 354.4 [MH+] Example 8 2-(2,5--Dioxoimidazolidin-4-y]-N-[2'(4-flaorophenayl)ethy]]-acetamide APC1-MS m/z: 280.3 [MH+] ]^xample 9 N-[2-(4-Bromophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetainide APCI-MS m/z: 340.3 ; 342.3 [MH+] Example 10 N-[2-(2,4-Dichlorophenyl)ethyl]--2-(2,5-dioxoinudazoIidin-4-yl)-acetamide APCI-MS m/z: 330.3 ; 332.3[MH+] jplxample 11 N-[2-(3'-ChIoro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 372.4 [MH+] Example 12 N-[2-(4'-Benzyloxy-biphenyl-4-yl)-ethyl]-2-(2,5.dioxoimidazolidin.4-yl)-acetomide APCIMS m/z: 444.5 [MH+] Example 13 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-thiophen-3-yl-phenyl)ethyl}-acetamidfi APCIMS m/z: 344.3 [MH+] Example 14 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-thiophen-2-yl-phenyl)ethyl]-acetamide APCI-MS m/z: 344.3 [MH+] Example 15 N-[2-(4'-ChIoro-biphenyl.4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 372.3 [MH+] Example 16 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methylsulfanyl-biphenyl-4-yl)ethyl]- acetamide APCI-MS m/z: 384.4 [MH+] Example 17 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-nitro-biphenyl-4-yl)ethyl]-acetamide APCIMS m/z: 383.4 [MH+] Example 18 2-(2,5>dioxoimidazolidin-4-yl)-N-[2-(4'-methyl-biphenyl-4.yl)ethyl]-acetamide APCI-MS m/z: 352.4 [MH+] Example 19 N-[2-(3'-Acetylamino-biphenyl-4-yl)ethyl3-2-{2,5-dioxoiinidazolidin-4-yl)-acetamide APCI-MS m/z: 395.4 [MH+] Example 20 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-naphthalen-2-yl--phenyl)ethyl]-acetamide APCI-MS m/z: 388.4 [MHl Example 21 N-[2-(3,5-Dichloro-bphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 406.3 ; 408.4 [MH+] Example 22 2-(2,5-dioxoimidazolidin-4-yl)-N-[2"(3'-methyl-biphenyl-4-yl)ethyl]-acetamide APCI-MS m/z: 352.4 [MH+] Example 23 N-[2-(4'Benzoftiran-2-yl-phenyl)ethyl]-2-(2,5-dioxoimdazolidin-4-yl)-acetamide APCI-MS m/z: 378.4 [MH+] Example 24 2-(2,5-Dioxoiniidazolidin-4-yl)-N-[2-(3'-methoxy-biphenyl-4-yl)ethyl]-acetamide APCI-MS m/z: 368.3 [MH+] Example 25 2-(2,S-Dioxoimidazolidin-4-yl)-N-(2-[l,l';4',l"]terphenyl-4-yIethyl)-acetamide APCI-MS m/z: 414.4 [MH+] Example 26 N-[2-(4'-AcetyI-biphenyl-4-yl)ethyl].2-(2,5-dioxoimidazolidin-4-yl).acetamide APCI-MS m/z: 380.4 [MH+] Example 27 N-[2-(4.Benzo[b]thiophen-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 394.4 [MH+] Example 28 N-[2-(4-Cyanomethyl-biphenyl-4'yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-actamide APCI-MS m/z: 377.4 [MH+] Example 29 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-pyridin-3-yl-phenyl)ethyl]-acetamide APCI-MS m/z: 339.4 [MH+] Example 30 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(lH-pyrrol-2-yl)phenyl]ethyl}-acetamide APCI-MS m/z: 327.4 [MH+] Example 31 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-furan-3-yl-phenyl)ethyl]-acetamide APCI-MS m/z: 328.4 [MH+] Example 32 2-(2,5-Dioxolmidazolidin-4-yl)-N-[2-(4-furan-2-yl-phenyl)ethyl]-acetamide APCI-MS m/z: 328.4 [MH+] Example 33 2.(2,S-dioxoimidazolidin-4-yl)-N-(2-thiophen-2-yl-ethyl)-acetamide APCI-MS m/z: 268.3 [MH+] Example 34 N-[2-(4-tert-Butylphenyl)ethyl]-2-(2,5-dioxoimidazolidin-4.yl)-acetamide APCI-MS m/z: 318.4 [MH+] Example 35 N-[2-(4-Chlorophenyl)-l-methylethyl}'2-(2,5-dioxoimidazolidin-4-yl)acetamide 1HNMR (400MHz,DMSO-d6): δ 10.55(1H, d); 7.88 (IH, dd);.7.76 (IH. d); 7.33-7.31 (2H. m); 7.21-7.19 (2H, m); 4.19-4.16 (IH, m); 3.94-3.88 (IH. ra); 2.77-2.32 (4H. m); 0.99 (3H, dd) APCIMS m/z: 310.3 [MH+] Example 36 N-{[l-(4-Chlorophenyl)cyclopropyI]methyl}-2-(2,5-dioxoimidazolidin-4-yl)acetamide 1H NMR (400MHz,DMSO-d6): δ 10.53(1H, d); 7.95 (IH, t); 7.73 (IH, s); 7.33-7.25 (4H. m); 4.18-4.15 (IH. m); 3.39-3.22 (2H, m); 2.54-2.37 (2H. ra); 0.90-0.88 (2H, m); 0.76-0.73 (2H, m) APCI-MS m/z: 322.3 [MH+] Example 37 N-2,3-Dihydro-lH-inden-2-yl-2-(2,5-dioxoimidazoIidin-4-yl)acetamide 1H NMR (400MHz,DMSO-d6): δ 10.54(1H, d); 8.24 (IH, d); 7.82 (IH. s); 7.22-7.20(2H. m); 7.16-7.13 (2H, m); 4.47-4.42 (IH. m); 4.22-4.19( IH, m); 3.19-3.12(2H. m): 2,80-2.72 (2H, m); 2.54-2.36 (2H, m) APCIMS in/z: 274.2 [MH+] B» GeiMtral procedure for preparation of (4-methvl-2.S-dtoxoimida2olidin-4*YlV acetamides I. tert-butyi(4-methyl-2,5-dioxoimidazolidin-4-yl)acetate (Formula Removed) Tert-butyl acetoacetate (200mg; 1.3mmol), KCN (165mg; 2.5mmol) and (NH4)2CO3 (605mg; 6,3mmol) was suspended in EtOH (2mL) and H2O (2mL) in a sealed tube. The mixture was heated to 85-90 °C and a solution was obtained, the heating was continued over night. The resulting slightly yellow solution was allowed to cool to roomtemperature and a precipitate was formed. The nuxture was neutralised with 5%NaHS04 (aq) and diluted with H2O (30mL). The slurry was extracted with EtOAc (2x50 mL). The organic phase was dried (Na2S04), filtered and evaporated to give the title compound as a colourless solid. Obtained 210 mg (73% yield). 1H-NMR(DMS0-D6): δ 10.58 (IH, s), 7.91 (IH, s), 2.76+2.39 (IH each, ABq), 1.35 (9H, s), 1.23(3H, s)ppm. (Formula Removed) II. (4-methyl-2,5-dioxoimidazolidin-4-yl)-acetic acid II. (4-methyl-2,5-dioxoimidazolidin>4-yl)-acetic acid Deprotection afforded the title compound. The following (4-inethyl-2,5-dioxoimidazolidin-4-yl)acetamides were prepared by coupling of the appropiate amine to (4-methyl-2,5-dioxoinudazolidin-4-yl)-acetic acid by the general procedure A above. Example 38 N-[2-(4-ChIorophenyl)ethyl]-2-(4-methyl-2,5-dioxolmidazolidin-4-yl)acetamide 1H NMR (400MHz,DMSO-d6): δ 10.42(1H. s); 7.94(1H. t); 7.35(1H, s); 7.35-7.31 (2H, m); 7.24-7.21 (2H, m) ; 3.21 (2H. q); 2.67 (2H, dd); 2.53-2.36 (2H, m); 1.21 (3H, s) APCI-MS m/z: 310.3 IMH+] Example 39 N-[2-(4-ChloropIienyl>propyl]-2-(4-methyl-2,S-dioxoimidiazoIidiii 1H NMR (400MHzDMSO-d6): δ10.42 (lH.m); 7.89-7.86 (IH. ra); 7.65-7.64 (IH, m); 7.35-7.32 (2H, m); 7.24-7.22 (2H, m); 3.19-3.09 (2a m); 2.87-2.77 (la m); 2.53-2.37 (2a m); 1.19 (3a d); 1.14 (3a d) APCI-MS m/z: 324.4 [MH+]J Example 40 N-[2-(4'-Cyano-l,l'-biphenyl-4-yl)ethyl].2-(4-methyl-2,5-dioxoimidazolidin-4- yl)acetaniide APCI-MS m/z: 377.3 [MH+] Example 41 N-[2-(4'-FIuoro-l,l'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetainide 1H NMR (400MHzDMSO-d6): δ 10.42 (IH.s); 7.99 (IH, t); 7.97-7.65 (3H, m); 7.56 (2H. d); 7.30-7.24 (4H, m); 3.28-3.23 (2H, m); 2.73-2.70 (2H. m); 2.54-2.39 (2H. m); 1.22 (3H. s) APCI-MS m/z: 370.4 [MH+] Example 42 2-(2,5-Dloxoinudazo]idin-4-yl)-N-[2-((4'-fluoro-l,l'-biphenyl-4-yl)propyl]-acetamide a) 2-(4-Bronio-phenyl)-propylamine 2-Phenyl-propylaminc (1g, 7.4mmol) was dissolved in n-hexane (30mL) and HBr/aq (5 drops) together with ZnBr on silica (1.75mmol/g, Ig). Br2 (14.8 mmol, 900µL) was slowly added and the slurry was stirred over night. The slurry was diluted with ethyl acetate (300mL) and washed with 2M Na2CO3 (300mL). The organic phase was dried over Na2S04, filtered and evaporated to dryness. Purification and separation of rcgioisomers was done on semi prop-HPLC C18-column (H2O.-CH3CN, 1% NHL4OAc buffer, gradient 10% to 60% CH3CN, 30 min). Yield 23% b) [2-(4-Bromo-phenyl)-propyl]-carbamic add tert-butyl ester 2-(4-Bromo-phenyl)-propylamine (18.7 mmol, 4g) was dissolved in 50mL THF (dry, mol sieves) and di-tert-butyl dicarbonate (1.2eq 23mmol 5g) was added slowly. The reaction mixture was stirred at room temperature for 1 hour before it was diluted with 300mL ethyl acetate and washed with 300mL sat, NaHCO3/aq. The organic phase was dried over Na2SO4, filtrated and evaporated to dryness. c) [2-(4'-Fluoro-bipheny-4-yl)-propyI]-carbamic add tert-butyl ester The BOC-protected amine obtained in b) above was dissolved in a mixture of 10mL toluene, 2.5mL ethanol and 2.5mL 2M Na2CO3/aq. PdCl2Cdppf) (0.03eq. 50mg) and 4-fluoroben2eneboronic acid (l.05eq, 2.1mmol) were added. The solution was degassed with nitrogen and the vessel was sealed before it was stirred overnight at 80°C. The reaction mixture was diluted with 50mL toluene and 50mL water. After mixing, the organic layer was transferred directly on to a silica column and purified by chromatography (toluene- ethyl acetate). d) 2-(4'-Fluoro-biphenyl-4-yI)-propyIamine To remove the protecting group the compound obtained in c) above was stirred in a mixture of 5mL cone. HCl in l0mL THF for 30 mm. The solution was neutralised with IM NaOH/aq and extracted with dichloromethane (2x). The combined organic layers was dried over Na2SO4, filtrated and evaporated to dryness. e) 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4' -fIuoro-1,1' -biphenyl-4-yl)propyl]- acetamide 600µL of a 0.15M solution in NMP of 5-hydantoin acetic acid was mixed with 98mg of polystyrene-bound carbodiimide resin (loading 1.28mmol/g). 340µL of a 0.3M solution of HOBT in NMP was added to the mixture and vortexed for 10 minutes before 200µL of a 0.3M solution in NMP of 2-(4'-fluoro-biphenyl-4-yl)-propylamine was added. The reaction mixture was vortexed overnight at room temperature in a sealed vessel. Resin was removed by filtration and the solution was evaporated to dryness. The product was purified on semi prep-HPLC C18-column (H2O:CH3CN, 0.1% TFA buffer, gradient 10% to 95% CH3CN, l0min). 1H NMR (400MHz,DMSO-d6): δ 10.55 (s, IH), 8.00 (s, IH), 7.76 (s, IH), 7.68 (dd, /= 8.7,5.5 Hz, 2H), 7.57 (d, J= 8.1 Hz, 2H), 7.32 - 7.25 (m, 4H). 4.22 - 4.17 (m. IH). 3.23 (dd, / = 20.7,6.3 Hz, 2H), 2.92 (q, 7 = 7.0 Hz, IH), 2.57 - 2.35 (m, 2H), 1.21 (d. /= 7.1 Hz, 3H). APCI-MS m/z: 370.2 [MH+] The following compounds were prepared according to methods analogous to Example 42 above. Example 43 N-[(lS,2r)-2-(4'-Methoxyblphenyl-4-yI)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide 1H NMR (400MHz,DMSO-d6): δ 10.44 (d, J = 7.6 Hz, IH). 8.18 (dd, 7 = 6-8,4.3 Hz. IH). 7.73 (5, IH), 7.54 (d, J = 8.9 Hz, 2H). 7.48 (d, 7 = 8.3 Hz, 2H), 7.13 (dd, J = 8.3.2.8 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 3.77 (s, 3H), 2.79 - 2.73 (m, IH), 2.56 - 2.46 (m, IH), 2.37 (d, 7= 15.2 Hz, IH), 1.90 (dt, 7 = 6.1, 3.1 Hz, IH). 1.23 (s, 3H), 1.17-1.09 (m, 2H). APCI-MS m/z: 394.3 [MH+] Example 44 N-[(15,2R)-2-(4'-Cyanobiphenyl-4-yl)cyclopropyl]-2.(4-methyl-2,5-dioxoimidazolidin- 4-yl)-acetamide APCI-MS m/z: 389.3 [MH+] Example 45 N-[(15,2R)-2-(4'-Acetylbiphenyl-4-yl)cycIopropyI]-2-(4-methyl-2,5-dioxoimidazolidin- 4'yl)-acetanude 1H NMR (400MHz,DMSO-d6): δ 10.44 (d, 7= 8.3 Hz, IH), 8.20 (dd, 7= 7.3,4.3 Hz, IH), 8.00 (d, 7 = 8.4 Hz, 2H), 7.78 (d, 7= 8.5 Hz, 2H), 7.73 (s, IH), 7.63 (d, 7 = 8.3 Hz, 2H), 7.21 (dd, 7 = 8.3, 3.1 Hz. 2H). 2.80 (dd, 7 = 7.4, 4.0 Hz, IH), 2.59 (s, 3H). 2.56 - 2.35 (m, 2H), 1.95 (tq, 7 = 6.2, 3.2 Hz, IH), 1.23 (s, 3H), 1.22 -1.13 (m, 2H). APCI-MS m/z: 406.3[MH+] Example 46 N-{(15,2R)-2-[4'-(Acetylamino)biphenyl-4-yI]cyclopropyl}-2-(4-methyl-2,5- dioxolmidazolidin-4-yl)-acetamide APCI-MS m/z: 421.3 [MH+] Example 47 N.[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide 1H NMR (400MHz.DMSO-d6): δ 10.43 (s, IH), 7.95 - 7.85 (m, 5H), 7.67 (dd, 7= 14.2, 8.5 Hz. 3H), 7.36 (dd. /= 8.3,1.7 Hz, 2H), 1.19 (s, 3H), 1.21 (d, /= 3.9 Hz, 3H), 3.20 (sextet, J = 6.8 Hz, 2H). 2.94 - 2.87 (m, H), 2.54 - 2.39 (m. 2H). APCI-MS m/z: 391.3 [MH+] Example 48 2-(2,S-Dioxoimidazolidin-4-yl)-N-[2-(3'-methoxybiphenyl-4-yl)ethyl]-acetamide 1H NMR (400MHZ,DMSO-D6): δ 10.56 (s, IH), 8.07 (t, 7= 5.5 Hz.lH). 7.80 (s, IH). 7.59 (d, 7 = 8.1 Hz, 2H), 7.36 (t, 7 = 8.0 Hz, IH). 7.30 (d, 7= 8.2 Hz. 2H), 7.20 (d, 7= 7.7 Hz, IH), 7.16 (t, 7 = 2.0 Hz, IH), 6.91 (dd, 7 = 8.1, 2.3 Hz, IH), 4.24 - 4.20 (m. IH), 3.82 (s. 3H), 3.34 - 3.26 (m. 2H), 2.75 (t, 7=7.3 Hz, 2H). 2.57 - 2.37 (m, 2H). APCI-MS m/z: 368.2 [MH+]] Example 49 N-I2-(4'-Cyano-3'-methylbiphaiyl-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4- yl)-acetamide 1H NMR (400MH2,DMSO-d6): δ10.41 (s. IH), 7.92 (t, 7= 5.6 Hz, IH), 7.81 (d, 7= 8.1 Hz, IH), 7.77 (s, IH), 7.69 - 7.62 (m. 4H), 7.34 (dd, 7 = 8.3, 1.7 Hz, 2H), 3.18 (t. 7= 6.5 Hz, 2H), 2.89 (dd, 7= 6,9,2.6 Hz, IH), 1.18 (s, 3H), 1.20 (d, 7= 4.1 Hz, 3H), 2.53 (s, 3H), 2.51-2.38 (m,2H). APCI-MS m/z: 405.3[MH+] Example 50 2-(2,5-dioxoimidazolidin-4-yI)-N-methyl-N-(2-phenylethyl)-acetamide APCI-MS m/z: 276.2 [MH+] Example 51 N-[l-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yI)-acetamide APCI-MS m/z: 296.1 [MH+] Example 52 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-hydroxy-l-methyl-2-phenylethyl)-acetamlde APCI-MS m/z: 292.3 [MH+] Example 53 N-{2-[4-(l,3-Benzodioxol-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4- yl)-acetamide APCI-MS m/z: 396.5 [MH+] Example 54 2-(2,5-DioxoimidazoIidin-4-yI)-N-[2-(3'-methoxybiphenyl-4-yl)propyI]-acetamide APCI-MS m/z: 382.4 [MH+] Example 55 N-{2-[3'-(Acetylamino)biphenyl-4-yl]propyl}-2-(2,5-dioxoimidazolidin-4-yI)- acetamide APCI-MS m/z: 409.5 [MH+]] Example 56 N-[2-(3'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazoadin-4-yI)-acetamide APCI-MS m/z: 394.4 [MlT] Example 57 N-[2-(4'-Acetylbiph«ayl-4-yl)propyl3-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 394.5 [MH+] Example 58 N-{2-[4-(l-Benzothien-2-)yl)phenyl}propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetaimde APCI-MS m/z: 408.4 [MH+] Example 59 N-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yI)-acetainide APCI-MS m/z: 377.4 [MH+] Example 60 N-[2-(4'-Cyanobiphenyl-4-yl)propyl3-2-(2,S-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 377.4 [MH+] Example 61 2-(2^Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-3'-methylbiphenyl-4-yl)propyI]-acetamlde APCI-MS m/z: 384.4 [MH+] Example 62 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[3'-(methylthio)biphenyl-4-yl3propyl}-acetamide APCI-MS m/z: 398.4 [MET] Example 63 2-(23-Dioxoimidazolidin-4-yI)-N-{2-[4-(6-methoxypyridin-3-yI)phenyl]propyl}- acetamide APCI-MS m/z: 383.4 [MH+] Example 64 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methoxy-3'-methylbiphenyl-4-yl)propyl]- acetamide APCI-MS m/z: 396.5 [MH+] Example 65 N-{2-[4-(2;3-Dihydro-l-benzofuran-5-yl)pheayl}propyl}-2-(2,5-dioxoimidazolidin-4- yl)-acetamide APCI-MS m/z: 394.5 [MH+] Example 66 2-(2,5-Dioxoimidazolidin-4-yI)-N-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}- acetamide APCI-MS m/z: 436.5 [MH+] Example 67 N-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyI]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 412.5 [MH+] Example 68 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-quinolin-3-ylphenyl)propyI]-acetamide APCI-MS m/z: 403.5 [MH+] Example 69 N-r2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyJ].2-(2,S-dioxoimidazolidin-4-yI)-acetamide APCI-MS m/z: 391.5 [MH+] Example 70 N-[5-(l,3-BenzodioxoI-5-yl)-2,3-dihydro-lH-inden-2-yI]-2-(2,5-dioxoinudazolidin-4-yl)-acetaniide APCI-MS m/z: 394,4 [MH+] Example 71 2-(2,5-Dioxomidazolidin-4-yI)-N-[5-(3-methoxyphenyl)-2,3-dihydro-lH-inden-2-yl]-acetamide APCI-MS m/z: 380.4 [MH+] Example 72 N-{5-I3-(Acetylamino)phenyl]-2,3-dihydro-lH-inden-2-yl}-2-(2,5-dioxoimidbzoIidijtt- 4-yl)-acetamide APCI-MS m/z: 407.5 [MH+] Example 73 N-t5-(3-Acetylphenyl)-2,3-dihydro-lH-mden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamide APCI-MS m/z: 392.4 [MH+] Example 74 N-[5-(4.Acetylphenyl)-2,3-dihydro-1H-inden-2-yl3-2-(2,5-dioxoimidazolidin-4-yI)- acetamide APCI-MS m/z: 392.5 [MH+]] Example 75 N-[5-(l-Benzothien-2-yl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazoUdin-4-yl)- acetatnide APCI-MS m/z; 406.4 [MH+] Example 76 N-[5-(3-Cyanophenyl)-2,3-dihydro-lH-mden-2-yl]-2-(2,5-dioxoimidazolidin-4.yI)- acetamide APCI-MS m/z: 375.4 [MH+] Example 77 N-[5-(4-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)- acetamide APCI-MS m/z: 375.4 [MH+] Example 78 2-(2,5-DioxoimidazoIidm-4-yI)-N-[5-(4-fluoro-3-methylphenyl)-2,3-dihydro-lH-inden- 2-yi]-acetamide APCI-MS m/z: 382.4 [MH+] Example 79 2-(2,S-Dioxoimidazolidin-4-yl)-N-{S-[3-(methylthio)phenyl3-2,3-dihydro-lH-inden.2- yl}-acetamide APCI-MS m/z: 396.4 [MH+] Example 80 2-(2,5-DioxoimidazoIidin-4-yl)-N-[S-(6-methoxypyridin-3-yl)-2,3-dihydro-lH-inden-2- yl]-acetamide APCI-MS m/z: 38l;4 [MH+] Example 81 2.(2,5-Dioxoimidazolidin-4-yI).N-(5-(4-methoxy-3-methylphenyl)-2,3-dihydro-lH-inden-2-yI]-acetamide APCI-MS m/z: 394.5 [MH+] Example 82 N-[5-(2,3-Dihydro-l-benzofuran-5-yl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5- dioxounidazoIidin-4-yl)acetamide APCI-MS m/z: 392.4 [MH+] Example 83 N-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-lH-inden-2-yl]-2-{2,5-dioxoimidazolidin-4- yl)-acetainide APCI-MS m/z: 410.5 [MH+] Example 84 N-[2-(4'-Fluorobiphenyl-4-yl)propyl]-2-{4-methyl-2,5-dioxoimidazolidin-4-yI)- acetamide APCI-MS m/z: 384.5 [MH+] Example 85 N-{2-[4-(l,3-Benzodioxol-5-yl)phenyl]propyI}-2-(4-methyl-2,5-dioxoimidazolidin-4- yl)-acetamide APCI-MS m/z: 410.5 [MH+] Example 86 N-[2-(3'-Methoxybiphenyl-4-yI)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide APCI-MS m/z: 396.5 [MH+] Example 87 N-{2-[4-(l-Ben2othien-2-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide APCI-MS m/z: 422.5 [MH+] Example 88 N-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide APCI-MS m/z: 391.5 [MH+] Example 89 N-[2-(4'-FIuoro-3'-methylbiphenyl-4-yI)propylJ-2-(4-methyl-2,5-dioxoimida8»Iidin-4- yl)-acetamidc APCI-MS m/z: 398.5 [MH+] Example 90 2-(4-Methyl-2,5-dioxoiraidazolidin-4-yl)-N-{2-[3'-(methylthio)biphenyl-4-yI]propyI}- acetamide APCI-MS ra/z: 412.5 [MH+] Example 91 N-{2-[4-(6-Methoxypyridin-3-yI)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4- yl)-acetamide APCI-MS m/z: 397.5 [MH+] Example 92 N-[2-(4'-Methoxy-3'-methylbiphenyl-4-yl)propyI]-2-(4-methyl-2,5-dioxoimidazolidin- 4-yl)-acetamide APCI-MS m/z: 410.5 [MH+] Example 93 N-{2-[4-(2,3-Dihydro-l-benzofuran-5-yl)phenyl}propyl}-2-(4-methyl-2,5- dioxoimidazolidin'4-yl)-acetainide APCI-MS m/z: 408.5 [MH+] Example 94 2-(4-Methyl-2,S-dloxoiinidazolidm-4-yI)-N-{2-[3'-(trmuoromethoxy)biphenyl-4. yI]propyl}-acetamide APCI-MS m/z: 450.5 [MH+] Example 95 N-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)- acetamide APCI-MS m/z: 426.5[MH+] Example 96 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-[2-(4-quiaolin-3-ylphenyl)propyl3-acetamide APCI-MS m/z: 417.5 [MH""] Example 97 N-[5-(4-FIuorophenyl)'2,3-dihydro-lH-mden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin- 4-y!)-acetamide APCI-MS m/z: 382.5 [MH+] Example 98 N-[5-(l,3-BenzodioxoI-5-yl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetainide APCI-MS m/z: 408.5 [MH+] Example 99 N-[5-(3-Methoxyphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5- dioxounidazo]idin-4-yl)acetamlde APCI-MS m/z: 394.5 [MH+] Example 100 N-{5-[3-(Acetylamlno)phenyl]-2,3-dihydro-1H-inden-2-yl}-2-(4-methyl-2,5- dioxoimidazolidin-4-yI)-acetamide APCI-MS m/z: 421.5 [MH+] Example 101 N-[5-(3-Acetylphenyl).2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin- 4-yl)-acetamlde APCI-MS m/z: 406.5 [MH+] Example 102 N-[5-(4-Acetylphenyl)-2;3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimdazolidin- 4-yl)-acetamide APCI-MS m/z: 406.5 [MH+] Example 103 N-[5-(l-Benzothien-2-yI)-2,3-dihydro-1H-mden-2-yl].2-(4-methyl-2,S-dioxoitnidazolidin-4-yl)-acetainide APCI-MS m/z: 420.5 [MH+] Example 104 N-[5-(3-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxounidazolidin. 4-yI)-acetamide APCI-MS m/z: 389.5 [MH+] Example 105 N-[5-(4-Cyanophenyl>2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin- 4-yl)-acetamide APCI-MS m/z: 389.5 [MH+] Example 106 N-[5-(4-Fluoro-3-methylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5- dioxouiudazolidin-4'yl)-acetamide APCI-MS m/z: 396.5 [MH+] Example 107 2-(4-Methyl-2^-dioxoimidazoIidin-4-yI)-N-{5-[3-(methylthio)pheny!]-2,3-daiydro-lH- inden-2-yl}-acetamide APCI-MS m/z: 410.5 [MH+] Example 108 N-[5-(6-Methoxypyridln-3-yl)-2,3-dihydro-lH-inden-2-yl3-2-(4-methyl-2-5 dioxoimidazolidin-4-yl)-acetamide APCI-MS m/z: 395.5 [MH+] Example 109 N-[5-(4-Methoxy-3.methylphenyl)-2,3-dihydro.lH-inden-2-yl]-2-(4-methyl-2,5-dioxoiinidazo]idin-4-yl)-acetanude APCI-MS m/z: 408.5 [MH+] Example 110 N-[5-(2,3-Dihydro-l-benzofuran-S.yl)-2,3-dihydro-lH-lnden-2-yl]-2-(4-methyl-2,5- dioxoimidazolidln-4-yI)-acetamide APCI-MS m/z: 406.5 [MH+] Example 111 2-(4-Methyl-2,5-dioxoimidazoIidin-4-yl)-N-{5-[3-(trifluoromethoxy)phenyl]-2,3 dihydro-lH-inden-2-yl}-acetamide APCI-MS m/z: 448.5 [MH+] Example 112 N-[5-(3,4"Dimethoxyphenyl)-2,3-dihydro-lH-inden-2-yI]-2-(4-methyl-2,5- dioxoimidazoUdin-4-yl)-acetamide APCI-MS m/z: 424.5 [MH+] Example 113 N-[5-(4-Cyano-3-methylphenyl)-2,3-dihydro-lH.inden-2-yl]-2-(4-methyl-2,5- dioxoimidazoIidin-4-yI)-acetamide APCI-MS m/z: 403.5 [MH+] Example 114 2-(2,5-Dioxoimidazolidin-4"yl)-N-(2-{4-[4(trifluoromethyl)phenoxy]phenyl}ethyl)- acetamide a) [2-(4-Hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 2-(4-Hydroxyphenyl)-cthylamine (36.5mmol, 5g) was dissolved in l00mL THF (dry, mol sieves) and di-tert-butyl dicarbonate (1.2eq 43.8mmol, 9.5g) was added slowly. The reaction mixture was stirred at room temperature for 1 hour before it was diluted with 700mL ethyl acetate and washed with 500mL sat. NaHCO3/aq. The organic phase was dried over Na2SO4, filtrated and evaporated to dryness. b) {2-[4-(4-Trifluoromethyl-phenoxy)-phenyl]-ethyl}-carbainic acid tert-butyl ester 0.5mmol of the BOC-protected amine obtained in a) above was dissolved in dichloromethane (5mL) together with copp6r(ir)acetate (O.Smmol, 90mg), powdered 4A mol sieves (app. l00mg) and4-(trifluoromethyl)benzeneboronic acid (Immol). After stirring the reaction mixture overnight at room temperature the slurry was filtered and purified by flash chromatography. c) 2-[4-(4-Trifluoromethyl-phenoxy)-phenyl]-ethylamine The BOC-group was removed by stirnng the compound obtained in b) above in hydrochloric acid/IHF (0.5mL cone. HCl /1.5mL THF) for 2 hours at room temperature before it was made basic by adding 10.5mL IM NaOH/aq. The free amine was extracted with 3xl0mL dichloromethane that was dried over Na2S04, filtrated and evaporated to dryness. Yield 0.32 mmol (62%). d) 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-{4-[4 (trifluoromethyl)phenoxy]- phenyl}ethyl)-acetamide The title compound was prepared by a method analogous to that described in Example 42e). 1H NMR (400MHz,DMSO-d6):δ 10.55 (s, IH), 8.05 (t, /- 5.6 Hz. IH), 7.79 (s, IH), 7.72 (d, 7= 8.8 Hz, 2H), 7.30 (d, /= 8.5 Hz, 2H), 7.08 (dd. 7 = 20.1, 8.5 Hz, 4H), 4.20 (dd, /= 6.2,4.8 Hz, IH), 3.29 (q, /= 6.8 Hz, 2H), 2.73 (t, /= 7.3 Hz, 2H), 2,57 - 2.36 (m, 2H). APCI-MS m/z: 422.3 [MH+] The following compounds were prepared according to methods analogous to Example 114 above. Example 115 2-{2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(4-methoxyphenoxy)phenyl]ethyl}-acetamide 1H NMR (400MHzJDMSO-d6): 6 10.54 (s, IH). 8.01 (t. 7 = 5.5 Hz, IH), 7.77 (s, IH), 7.16 (d, J - 8.6 Hz. 2H), 6.97 - 6.91 (m. 4H). 6.83 (d, J- 8.5 Hz. 2H), 4.18 (dd, 7 = 6.2.4.6 Hz, IH), 3.72 (s, 3H), 3.22 (q, /= 6.8 Hz, 2H), 2.65 (t, 7= 7.4 Hz. 2H), 2.55 - 2.33 (m, 2H). APCI-MS m/z: 384.3 [MH^J Example 116 2-(2,5-Dioxoimidazolidin-4-yI)-N-(2-{4-[4-(trifluoromethoxy)phenoxy]phenyl}ethyl)- acetamide 1H NMR (400MH2,DMSO-d6): δ 10.55 (s, IH), 8.04 (t, 7= 5.5 Hz, IH), 7.79 (s. IH), 7.37 (d, 7 = 8.6 Hz, 2H), 7.25 (d, 7 = 8.5 Hz, 2H), 7.07 (td. 7 = 6.4,4.0 Hz, 2H), 6.99 (d, 7 = 8.5 Hz, 2H), 4.20 (dd, 7= 6.1,4.7 Hz, IH), 3.27 (q, 7 = 6.8 Hz, 2H), 2.71 (t, 7=7.4 Hz, 2H), 2.57 - 2.35 (m, 2H). APCI-MS m/z: 438.3 [MH+] Example 117 N-{2-[4-(4-Chlorophenoxy)phenyl]ethyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide 1H NMR (400MHz,DMSO-d6): δ 10.55 (s. IH). 8.04 (t, 7= 5.5 Hz. IH), 7.79 (s, IH), 7.41 (dd, 7= 12.4,3.5 Hz, 2H). 7.24 (d, 7 = 8.5 Hz, 2H), 7.01 - 6.95 (m. 4H), 4.20 (dd.7 = 6.1. 4.7 Hz, IH), 3.26 (q. 7 = 6.8 Hz, 2H), 2.70 (t, 7= 7.4 Hz, 2H), 2.57 - 2.34 (m, 2H). APCI-MS m/z: 388 J [MH^] Example 118 N-{2-[4-(4-Acety]phenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetaraide 1H NMR (400MHz,DMSO-d6): δ 10.55 (s, IH), 8.05 (t, /= 5.7 Hz. IH), 7.97 (d. /= 8.9 Hz. 2H), 7.80 (s, IH), 7.29 (d, 7= 8.5 Hz, 2H), 7.04 (t, 7= 8.8 Hz, 4H). 4.22 - 4.19 (m, IH), 3.33 - 3.24 (m, 2H), 2.73 (t, / = 7.2 Hz, 2H), 2.58 - 2.35 (m, 5H). APCI-MS m/z: 396.3 [MH+] Example 119 2-(2,5-DioxoimidazoIidin-4-yl>N-{2'[4-(pyridin-3-yloxy)phenyl]ethyl}-acetamide APCI-MS m/z: 355.3 [MH+] Example 120 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-{4-[(6-methoxypyridin-3-yl)oxy]phenyl}ethyl)- acetamfde APCI-MS m/z: 385.1 [MH+] Example 121 N-{2-[4-(4-Cyanophenoxy)phenyl]ethyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetaraIde 1H NMR (400MHz,DMSO-d6): δ 10.57 (s, IH), 8.05 (t, J = 5.5 Hz, IH), 7.81 (d, J = 8.9 Hz, 2H), 7.79 (s, IH), 7.30 (d, J = 8.5 Hz, 2H), 7.06 (d, J = 8.8 Hz, 4H), 4.20 (dd, /= 6.1, 4.8 Hz, IH), 3.28 (q, 7= 6.7 Hz, 2H), 2.73 (t, 7= 7.3 Hz, 2H), 2.56 - 2.36 (m, 2H). APCI-MS m/z: 379.3 [MH+] Example 122 2-(2,5-Dioxoimidazolidm-4-yl)-N-{2-[4-(4-methylphenoxy)phenyl]ethyl}-acetamide 1H NMR (400MHz,DMSO-d6): δ 10.55 (s, IH), 8.03 (t, 7= 5.5 Hz, IH), 7.79 (s, IH), 7.21 - 7.16 (m, 4H), 6.89 (d, 7 = 8.2 Hz, 4H), 4.20 (dd, 7 = 6.0,4.5 Hz, IH), 3.25 (q, 7 = 6.8 Hz, 2H), 2.68 (t, 7 = 7.4 Hz, 2H), 2.56 - 2.35 (m, 2H), 2.28 (s, 3H). APCI-MS m/z: 368.3 [MlT] Example 123 2-(2,5-dioxoimidazolidin-4-yl)-N-{2-[4-(4-fluorophenoxy)phenyl]ethyl}-acetamlde 1H NMR (400MH2 DMSO-d6): δ 10.53 (s, IH), 8.02 (t. J = 5.5 Hz, IH), 7.77 (s, IH). 7.23 - 7.17 (m, 4H). 7.02 (tt. 7 = 4.5,2.3 Hz, 2H), 6.90 (d, 7 = 8.5 Hz, 2H), 4.18 (dd. 7 = 6.0. 4.7 Hz, IH), 3.24 (q, 7= 6.8 Hz, 2H), 2.67 (t, 7 = 7.3 Hz, 2H), 2.54 - 2.33 (m, 2H). APC1-MS m/z: 372.3 [MH+]] Example 124 N-(2-Biphenyl-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimdazolidin-4-yl)-acetamide a) 4-Phenylphenyloxirane 4-Phenyl-(α-bromoacetophenone), 8.25 g (0.030 mol), was slurried in methanol (150 mL). Sodium borohydride (3.80 g; 0.10 mol) was added in portions to give an exothennal reaction and a homogeneous reaction mixture. After 20 hours, water (600 mL) was added and the mixture was extracted with dichloromethane (500 mL). The organic phase was evaporated to give 7.25 g of crude product. NMR analysis showed mainly a 1:1 mixture of epoxide and vicinal brorao alcohol. b) 2-Amino-l-biphenyl-4-yl-ethanol The product mixture obtained in a) above was dissolved in THF (ca 100 mL) and a large excess of concentrated ammonia and ethanol was added to give a homogeneous system. TLC analysis after 4 hours showed only starting materials. A slight increase in temperature gave scarce improvement and the mixture was finally heated to 70° C in a sealed vessel for 20 hours. TLC analysis showed absence of starting materials and NMR analysis showec a complex mixture of products. The solvents were evaporated and dichloromethane (150 mL) was added to give a precipitate. The mixture was filtered and the solid, about 3.8 g, and filtrate was analysed with TLC and NMR. Analyses showed mixmres of products but with, possibly, expected product in the solid phase. A sample of the solid (1.04 g) was purified by silica gel chromatography (200 mL) using dichloromethane/ methanol/ concentrated ammonia (90 +10+1) as eluant. Evaporation of pure fractions gave 0.62 g of the sub-titled compound. c) N-(2-BiphenyI-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimldazolidm-4-yl)-acetainide The title compound was prepared by a method analogous to that described in Example 42e). 1H NMR (400MHz,DMSO-d6): δ10.57 (s, IH), 8.10 (q, 7 = 5.8 Hz, IH), 7.79 (s, IH), 7.64 (t. 7 = 8.5 Hz, 4H), 7.45 (q, 7 = 7.7 Hz, 4H). 7.35 (t. 7 = 7.3 Hz, IH), 5.49 (s, IH). 4.66 (t, 7= 3.7 Hz, IH). 4.26 - 4.17 (m, IH), 3.20 - 3.09 (ra, IH), 2.59 (dt, 7= 15.5.3.5 Hz, IH), 2.52 - 2.39 (m, 2H). APCI-MS ra/z: 336.3 [MH+] Example 125 N-[2-(l,l'-Biphenyl-4-yI)-2-methoxyethyl]-2.(2,5-dioxoimidazoIidin-4-yl)-acetamide a) 4-(2'Amino-l-methoxyethyl)-biphenyl 4-Vinyl-biphenyl, 1.70 g (9.4 mmol), was dissolved in methanol (10 mL) and dichloromethane (15 mL). Bromine, 0.48 mL (9.4 mmol), dissolved in methanol (10 mL) was added over 30 minutes and TLC analysis showed complete reaction. The mixture was diluted with dichloromethane and added to an aqueous solution of sodium hydrogen sulphite and the mixture was shaken. The dichloromethane phase was washed with aqueous sodium hydrogen carbonate and water and evaporated to give 2.81g product. The product was purified by silica gel chromatography silica gel (200 mL) with heptane/ ethyl acetate (95 + 5) to give 1.00 g (39 %) of pure 4-(2-bromo-l-methoxy-ethyl)-biphenyl. 4-(2-Bromo-l-methoxyethyl)-biphenyl, 1.00 g (3.64 mmol), was dissolved in ethanol (20 mL) and added to a large excess of concentrated ammonia (20 mL). The mixture was heated to 100° C in a sealed vessel for 16 hours and evaporated. Chromatography on silica gel (180 mL) with dichloromethane followed by dichloromethane/ methanol/ concentrated ammonia (90 + 10 + 1) gave 0.47 g (61 %) of the sub-titled compound. b) N-[2-(l,l'-Biphettyl-4-yl).2-methoxyethyl]-2-(2,5-dioxoiinidazolidin-4-yI)-acetamide The title compound was prepared by a method analogous to that described in Example 42e). 1H NMR (400MHzIDMSO-d6): δ10.56 (s, IH), 8.16 (d, 7 = 5.5 Hz, IH), 7.78 (d, J = 62 Hz, IH), 7.70 - 7.64 (m, 4H), 7.47 (t. 7 = 7.6 Hz, 2H), 7.42 - 7.34 (m, 3H), 4.29 (dt, 7 = 7.8, 5.0 Hz, IH), 4.23 - 4.19 (m, IH), 3.19 (s, 3H), 2.61 - 2.53 (m, 2H), 2.50 - 2.39 (m. 2H). APCI-MS m/z: 368.2 [MH+] Example 126 N-[2-(l,l'-Blphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yI)-N-methylacetamide a) (4-PhenyIphenethyl)-N-methylamine 4-Phenylphenethyl amine, 0.48 g (2.4 mmol), was added to an excess of methyl formate (5 mL) and dichloromethane (5 mL) was added to improve solubility. The heterogeneous reaction mixture was refluxed to give a solution within 20 hours. NMR analysis of a sample showed almost complete conversion to N-formyl amine. The reaction mixture was evaporated to give 0.47 g (87%). The formyl compound, 0.47 g (2.09 mmol), was dissolved in THF and 2.1 mL of 1,0 M lithium aluminium hydride (2.1 mmol) in THF was added. TLC analysis after 20 hours showed only starting material and 2 niL (2 mmol) of lithium aluminium hydride solution was added. Analysis after 1 hour showed starting material and the mixture was heated to reflux. After 1.5 hours a precipitate was formed, the starting material consumed and tetrahydrofuran (15 ml) was added. The mixture was quenched by successive addition of water (0.15 g), 15 % aqueous sodium hydroxide (0.15 g) and water (0,45 g). The mixture was filtered and evaporated to give 0.33 g crude product. The crude product was purified by silica gel chromatography (100 mL) using dichioromethane/ methanol/ concentrated ammonia (90 + 10 + 1) as eluanL Evaporation of pure fractions gave 78 mg (18 %) of the sub-titled compound. b) N-[2-(1,1'-BiphenyI-4-yI)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl).N-methylacetamide The title compound was prepared by a method analogous to that described in Example 42e). APCI-MS m/z: 352.3 [MH+] Example 127 2-(2,5-Dioxoimida2oIidin-4-yI)-N-[2-(4-phenyIethynyl-piperidin-l-yl)ethyl]-acetamide a) 4-(Phenylethynyl)piperidine N-BOC-4-ethynylpiperidin, 0.5 g (2.40 mmol), and iodobenzene, 0.29 mL (2.64 mmol) were dissolved in triethylamine (9 mL) and argon was passed through for a few minutes. Copper(I) iodide, 0.087 g (0.5 mmol), and bis[triphenylphosphine]palladiiun dichloride, 0.070 g (0.1 mmol), were added and the mixture was heated to 82'C in a closed vessel for 17 hours. TLC analysis indicated complete reaction. Triethylamine was evaporated and the mixture was purified by silica gel chromatography (75 mL) using heptane/ethyl acetate (4 + 1) as eluant. Evaporation of pure fractions gave 0.497 g (73 %) of N-BOC-4-(phenylethynyl)piperidine. The protected piperidine, 0.497 g (1.74 mmol), was dissolved in dichioromethane and trifluoroacetic acid (1 mL) was added. The reaction was completed within 20 hours and the mixture was evaporated to give an oil. NMR analysis showed pure ammonium trifluoroacetate, contaminated with trifluoroacetic acid. The product was dissolved in dichioromethane and extracted with aqueous sodium hydrogen carbonate and water. Evaporation of solvent gave 0.284 g (88 %) of the sub-titled compound. b) 2-[4-(PhenylethynyI)piperidin-l-yl]ethanamine 4-(Phenylethynyi)piperidine (0.5 mmol, 92mg) was dissolved in acetonitrile (anhydrous 4A, 4mL) together with bromoethylphtalimide (0.5mmol, 128mg) and K2CO3 (2nimoI, 276mg). The reaction mixture was heated to reflux for 3hours, diluted with ethyl acetate (50mL) and washed with HCl/aq (IM, 50mL). The organic phase was dried over Na2SO4, filtered and evaporated to dryness. The protection group was removed by stirring the compound in methylamine (33% in ethanol, 5mL) for another 3 hours. The mixture was evaporated, diluted with ethyl acetate (50mL) and washed with NaOH (IM, 50raL). The organic phase was dried over Na2S04, filtered and evaporated to dryness. The crude product was used without further purification. c) 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-phenylethynyl-piperidin-l-yl)ethyl]-acetamide The title compound was prepared by a method analogous to that described in Example 42e). 1H NMR (4OOMHZ.CDCI3): δ 9.96 (s. IH), 9.67 (s, IH), 8.23 (s, IH). 7.34 (dd. 7= 66.3, 28.1 Hz, 5H), 4.35 (s, IH), 3.82 -1.88 (m, 15H). APCI-MS m/z: 369.3 [MHl Example 128 N-{2-[(4-Bromobenzyl)oxy]ethyl}-2-(2,5-dioxoimidazolidin-4-yl)acetamide a) 2-(4-Bromo-benzyloxy)-ethylaraine hydrochloride Sodium hydride (60 % in oil, 0.613 g, 15 mmol) was added in small portions over 5 minutes to a solution of tert-butyl N-(2-hydroxyethyI)-carbamate (1.771 g, 10.99 mmol), 4-bromobenzylbromide (2.676 g, 10.708 mmol) in dimethyl formamide (50 ml). The mixture was stirred for 2 hours at ambient temperature under argon. The mixture was partitioned between water (250 mL), ethyl acetate (50 mL) and heptane (50 raL). The organic phase was washed two times with water (30 mL). Evaporation afforded 3.13g of a clear oil. The oil was stirred in 2.5 M HCl in ethyl acetate (50 inL) for 2 hours. Filtering and washing with ethyl acetate afforded the sub-titled compound (2.256 g, 98.1 % yield). 1HNMR (300 MHz, DMSO-dc): δ 8.16 (3H, bs); 7.55 (2H, d); 7.36 (2H, d); 4.51 (2H, s); 3.64 (2H, t); 2.99 (2H, t). APCI-MS m/z: 229.9; 231.9 [MH+] b) N-{2-[(4-bromobenzyl)oxy]ethyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetainide The title compound was prepared by a method analogous to that described in Example 42e). 1HNMR (300 MHz, DMSO-de): δ 10.56 (IH. s); 8.08 (IH, t); 7.81 (IH, s); 7.54 (IH, d); 7.30 (IH. d); 4.45 (2H, s); 4.20 (IH, m); 3.25 (2H, q); 2.50 (2H, p); 2.50 (2H, m). APCI-MS m/z: 370; 372 [MH+] Example 129 2-(1,1-Biphenvl-4-yI)-2-oxoethyl(2.5-dioxoimidazolidin-4-yl)acetate Hydantoin acetic acid (109 mg, 0.69 mmol), 2-bromo-4'-phenylacetophenone (191 mg, 0.69 mmol) and N-ethyl-diisopropylamine (120 jil, 0.70 mmol) were stirred in dimethylformamide (5.0 mL) at 50°C for 3 hours. Evaporation and chromatography on silica (dichloromethane/methanol: 100/3) afforded 123 mg of the title compound in 50.1 % yield. 1HNMR (300MHz. DMSO-d6): δ 10.68 (IH, s); 8.06 (2H, d); 7.90 (IH, s); 7.87 (2H, d); 7.77 (2H, d); 7.55-7.42 (3H. m); 5,55 (2H, d); 4.32 (IH, dt); 2.90 (2H, d). APCI'MS m/z: 353.1 [Mit] Pharmacological Example Isolated Enzyme Assay Recombinant human MMP 12 catalytic domain may be expressed and purified as described by Parkar A.A. et al, (2000), Protein Expression and Purification, 20; 152. The purified enzyme can be used to monitor inhibitors of activity as follows; MMP12 (50 ng/ral final concentration) is incubated for 60 minutes at room temperature with the synthetic substrate Mac-Pro-Cha-Gly-Nva-ffis-Ala-Dpa-NH2 in assay buffer (O.IM "Tris-HCI" (trade mark) buffer, pH 7.3 containing 0. IM NaCl, 20mM CaCla, 0.020 mM ZnCi and 0.05% (w/v) "Brij 35" (trade mark) detergent) in the presence (5 concentrations) or absence of inhibitors. Activity is determined by measuring the fluorescence at ex 320nm and em 405nm. Percent inhibition is calculated as follows: % Inhibition is equal to the [Fluorescenceplus inhibitor - Fluorescencebackground} divided by the [Fluorescenceminus inhibitor-Fluorescence backgroundl For example, the following table shows the IC50 figures for a representative selection of compounds according to the invention when tested in the MMP12 enzyme assay. (Table Removed) WE CLAIM: 1. A metalloproteinase inhibitor compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof (Formula Removed) wherein X represents an oxygen atom or a group NR4 or CH2; Y represents NH or N-methyl; Z1 and Z2 each independently represent an oxygen or sulphur atom, provided that at least one; of Z1 and Z2 represents an oxygen atom; Either R1 represents hydrogen or a group selected from C1-C6 alkyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom: selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least One substituent selected from halogen, hydroxyl, cyano, carboxyl, -NR5R6, -C0NR7R0, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylcarbonyl)oxy), -S(0)m C1-C6alkyl where m is 0, 1 or 2, C1-C6alkylsulphonylamino, C1-C6 alkoxycarbonyl(amino), benzyloxy and a saturated or unsaturated 5- to 6- membered ring which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring in turn being optionally substituted with at least one substituent selected from halogen, hydroxyl, 0x0, carboxyl, cyano, C1-C6 alkyl, C1-C6 alkoxycarbonyl and C1-C6hydroxyalkyl, R2 represents hydrogen or C1-C6 alkyl, and R3 represents hydrogen or C1-C6 alkyl, or R1 and R2 together with the carbon atoms to which they are attached form a saturated 5- to 6* membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R3 is as defined above, or R2 and R3 together with the carbon atom to which they are attached form a satvirated 5- to 6- membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R1 is as defined above; R4 represents hydrogen or C1-C6 alkyl; R5, R6, R7 and R8 each independently represent hydrogen or C1-C6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C1-C6 alkoxy; L represents -CH2C(0)-or-C(0)CH2-, or L represents a C2-C6 alkyl or C2-C6 alkynyl group optionally interrupted or terminated by at least one moiety selected from O, NH, S, SO, SO2 and C(0), or L represents a C3-C5 cycloalkyl, methyl C3-C6cycloalkyl or C3-C6 cycloalkylmethyl group, each of the recited groups being optionally substituted with at least one substituent selected from hydroxyl, halogen, C1-C4alkyl, C1-C4haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy, or L represents a C3-C4 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G2 to form a ring; G2 represents a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C1-C6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C2-C6 alkenyl, C1-C6alkoxy (optionally substituted by one or more halogen atoms), -S(0)nC1-C6 alkyl where n is 0, 1 or 2, C1-C6 alkylcarbonyl (amino), C1-C6alkylcarbonyloxy, phenyl, benzyloxy, -NR9'R10 and a group of formula (Formula Removed) R9 and R10 each independently represent hydrogen or C1-C6 alkyl optionally substituted by at least one substituent selected from hydroxy 1, halogen and C1-C6 alkoxy; M represents a bond or -0-, -S-, -C = C-, -CH2O- or -OCH2-; G3 represents an unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C1-C6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C2-C6 alkenyl, C1-C6 alkoxy (optionally substituted by one or more halogen atoms), -S(O)tC1-C6 alkyl where t is 0, 1 or 2, C1-C6 alkylcarbonyl(amino), C1-C6 alkylcarbonyloxy, phenyl, benzyloxy and -NR11R 12and R11 and R12 each independently represent hydrogen or C1-C6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C1-C6 alkoxy. 2. A compound as claimed in claim 1, wherein x represents a group NR4. 3. A compound as claimed in claim 2, wherein R4 represents hydrogen. 4. A compound as claimed in any one of claims 1 to 3, wherein Y represents NH. 5. A compound as claimed in any one of the preceding claims, wherein Z1 and Z2 both represent an oxygen atom. 6. A compound as claimed in any one of the preceding claims, wherein L represents a C2-C4 alkyl group optionally interrupted or terminated by one or two moieties independently selected from O, NH, S, SO, SO2 and C(0), or L represents a C3-C6 cycloalkyl, methylC3-C6 cycloalkyl or C3-C6 cycloalkylmethyl group, each of the recited groups being optionally substituted with one or two substituents independently selected from hydroxyl, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy. 7. A compound as claimed in any one of claims 1 to 5, wherein L represents a C3-C4 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G2 to form a ring. 8. A compound as claimed in claim 7, wherein the 5- to 10-membered ring system of G2 is phenyl. 9. A compound as claimed in any one of claims 1 to 7, wherein, in G2, the saturated or unsaturated 5- to 10-membered ring system is selected from cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofiirany], tetrahydropyranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl. thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl. 10. A compound as claimed in any one of the preceding claims, wherein, in G3, the unsaturated 5- to 10-membered ring system is selected from cyolopentenyl, cyclohexenyl, phenyl, naphthyl, benzofuranyl, beuzothienyl, benzodioxolyl, quinolinyl, 2,3- dihydrobenzofuranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl. 11. A compound as claimed in claim 1 which is selected from the group consisting of: 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-biphenyl-4-yl)-ethyl]-acetamide, N-[2-(4'-Cyano-biphenyl-4-yl)-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-phenyl-cyclopropyl)-acetamide, N-[2-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoinzidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(7-methyl-lH-indol-3-yl)ethyl]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-phenoxyphenyl)ethyl] -acetamide, 2-(2,5-Dioxoimidazolidin-4-yI)-N-[2-(4-fluorqphenyl)ethyl]-acetamide, N-[2-(4-Bromophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(2,4-Dichlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(3-Chloro-biphenyl-4-yl)-ethyl]-2-(2;5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(4-Benzyloxy-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yI)-N-[2-(4-thiophen-3-yl-pheayl)ethyl]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-thiophen-2-yl-phenyl)ethayI]-acetamide N-[2-(4'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-(dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin--4-yl)-N-[2-(4'-methylsulfanyl-biphenyl-4-yl)-ethyl]-cetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-nitro-biphenyl-4-yl)ethyl]-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methyl-biphenyl-4-yl)ethyl]-acetamide N-[2-(3'-Acetylamino-biphenyl-4-yl)ethtl]-2-(2,5-dioxoinaidazolidin-4-yl)-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-naphthalen-2-yl-phenyl)ethyl]-acetamide N-[2-(3'5-Dichloro-biphenyl-4-yl)etheyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide 2-(2,5-Dioxoimidazolidin4-yl)-N-[2-(3'-methyl-biphenyl-4-yl)ethyl]-acetamide N-[2-(4-Bonzofuran-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-(3-methoxy-biphenyl-4-yl)ethyl]-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-[1.1;.4', 1 "]terphenyl-4-ylethyl]-acetamide, N-[2-(4'-Acetyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimodazolidin-4-yl)-acetamide, N-[2-(4-Berizo[b]thiophen-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-etamide, N-[2-(4'-Cyraomethyl-biphenyl-4-yl)ethyl3-2-(2,5-dioxoiniidazolidin-4-yl)-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-pyridin-3-yl-phenyl)ethyl]-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-( lH-pyrrol-2-yl)phenyl]ethyl} -acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-furan-3-yl-phenyl)ethyl]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yI)-N-[2-(4-furan-2-y1-phenyl)ethyl]-acetamide, 2-(2,5-Dioxoinikla2olidln-4-yl)-N-{2-thiophen-2-yl-ethyl)-acetamide, N-[2-(4-tert-ButylphenyI)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide N-[2-(4-Chlorphenyl)-l-methylethyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide N-{[1-{4-Chlorophenyl)cyclopropyl]methyl) -2-(2.5-dioxoimidazolidin-4-yl)acetamide, N-2,3-Dihydro-1H-inden-2-yl-2-{2,5-(dioxoimidazolidin-4-yl)acetamide, N-[2-(4-Chlorophenyl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetam N-[2-(4-Ch]oropbenyl)pn3pyI]-2-(4-methyl-2,5-dioxolmidazGlidi N-[2-(4'-Cyano-1,1 •-biphenyl-4-yl)ethyl]-2-(4-nwthyl-2,5-dioxoimidazolidin-4-yl)acetamide, N-[2-(4'-Fluoro-1,1 -biphenyl-4-yl)ethyl3-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide, 2-(2,5-Dioxoimidazolidin-4-yl0-N-[2-(4'-fluoro-l, ,1-biphenyl-4-yl)propyl]-acetamide, N-[(1.5,2R)-2-(4'-Methoxybiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dloxoimidazolidin-4-yl)-acetamide, N--[(l.S,2R)-2-(4'-Cyanobiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[(1S.2R)-2-(4-Acetylbipheayl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-{(15;2R2)-[4'-(Acetylamino)biphenyl-4-yl]cyclopropyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-y])acetamide, N-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidalidin-4-yl)-N-[2-(3'-methoxybiphenyl-4-yl)ethyl]-acetamide N-[2-(4-Cyano-3'-methylbiphenyl-4-yl)propy]]-2-(4-methyl-2,5-dioxoimidazolidin-4-y])-acetairade, 2-(2,5-Dioxoimidazolidin-4-yl)-N-methyl-N-(2-phenylethyl)-acetamide, N-[l-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2.5-Dioxoimidazolidin-4-yl)-N-(2-hydroxy-1-methyl-2-phenylathyl)-acetaimide, N-{2-[4-(l,3-Benzodioxol-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-methoxybiphenyl-4-yl)propyl]-acetamide N-{2-[3'-(Acetylamino)biphenyl-4-yl]propyl}-2-(2,5-dioxoimidazolid-4-yl)-acetamide, N-[2-(3'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide N-[2-(4-Acetyliphenyl-4-yl)propyl]-2-(2,5-dioxoilmidazolidin-4-yI)-acetamide, N-{2-[4-(l-Benzothien-2-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide. N-[2-(3'-Cyanobiphenyl-4-yl)propyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide. N~[2-(4-Cyanobiphenyl-4-yl)-propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamidin, 2-(2,5-Dioxoimidalidin-4-yl)-N-{2-(4'-fluoro-3-methylbiphenyl-4-yl)-propyl]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[3-(methylthio)biphenyl-4-yl]ppyl) -acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(6-methoxypyridin-3-yl)pheoyl]propyl}-acetamide. 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methoxy-3-methylbiphenyl-4-yl)-propyl]-acetamide, N'-{2-[4-2,3-Dihydro-l-benzofuran-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N- (2- [3"-(trifluoromethoxy)biphenyl-4-yl]propyl}-acetamide, N-(2-(3,4'-Dimethoxybiphenyl-4-yl)propyl]-2-(2,5-dioxoiinidazolidin-4-yI)-acetamide. 2-(2,5-Dioxoimidazolidin-4-yl)-N-12-(4-quinolin-3-ylphenyl)propyl]-acetamide, N-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl) acetamide, N-[5-(l,3-BenzodioxoI-5-yl)-2.3-dihydro-IH-inden-2-yI3-2-(2.5-dioxoimidazoli. yl)-acetaxnide, 2-(2,5-Dioxoimidazolidin-4-yl)-N'-[5-{3-methoxyphenyl)-23-dihydio-lH--inden-acetamide, N-{5-[3'(Acetylamino)phenyl]-2,3-dihydro-lH-inden-2-yl)-2-(2,5-dioxoimidaz 4-yI)-acetamide, N-[5-(3-Acetylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxourudazolidin-4-: acetamide, N-[5-(4-Acetylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-: acetamide, N-[5-(I-Benzothien-2-yl)-2,3-dihydro-lH-inden-2-yl]-2-(2,5-dioxoimidazolidin-acetamide, N-[5-(3-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl}-2-(2,5-dioxoimidazolidin-4-yl acetamide, N-[5-(4-CyanophenyI)-2,3-dihydro-lH-inden-2-yl]-2-C2,5-dioxoimidazolidin-4-} acetamide, 2-(2,5-Dioxoimidazolidin-4-y])-N-[5-(4-fluoro-3-methaylphenyl)-2,3-dihydro-lH inden-2-yl]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N- (5-[3-(methylthio)phenyl]-23-dihydn-lH-in yl}-acetamide. 2-{2,5-Dioxoimidazolidin-4-yI)-N-[5-(6-methoxypyridin-3-yl)-2,3-dihydio-lH-in 2-yI]-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-(4-methoxy-3-methylphenyl)-2,3-dihydro-; N-[2-(4'-Fluorobiphenyl-4-yI)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-{2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyI}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(3'-Methoxybiphenyl-4-yl)propyl3-2-(4-methyl-2,5-dioxoimidazolidin-yl)-acetamide, N-C2-[4-(l-Benzothien-2-yl)phenyl]propyl)-2-(4-methyl-2,5-dioxoimidazolidin-4-yl) acetamide, N-[2-(3-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(4-Fluoro-3'-methylbiphenyl-4-yI)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetainide, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{2-[3-(methylthio)biphenyl-4-yl]propyl)-acetamide, N-{2-[4-(6-Methoxypyridin3-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[2-(4'-Methoxy-3'-methylbiphenyI-4-yI)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetaimde, N-{2-[4-(2,3-Dihydro-l-benzofuran-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetainide, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{2-[3-(trifluoromethoxy)biphenyl-4-yl]propyl} -acetamide, N-[2-(3,4'-Dimthoxybiphenyl-4-yI)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-{4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-[2-(4-quinolin-3-ylphenyl)propyl]-3-acetamide, N-[5-(4-Fluorophenyl)-2.3-dihydro-lH-inden-2-yl3-2-(4-methyl-2.5-dioxoimidazolidin-4-yl)-acetamide. N-[5-(l,3-Benzodioxol-5-yl)-2.3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide. N-(5-(3-Methoxyphenyl)-2,3-dihydro-IH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-{5-[3-(Acetylamino)phenyl]-2,3-dihydro-lH-inden-2-yl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yI)-acetamide, N-[5-(3-Acetylphenyl)-2,3-dihydro-lH-inden-2-y]]-2-(4-methyl-2,5-dioxoimiudazolidin-4-yl)-acetamide, N-[5-(4-Acetylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(l-Benzothien-2-yl)-2,3-dibydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidio-4-yl)-acetamide, N-[5-(3-Cyanophenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(4-Cyanophenyl)-2.3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-}yl)-acetamide, N-[5-(4-Fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{5-[3-(methylthio)phenyl]-2,3-dihydro-lH-inden-2-yl }-acetamide, N-[5-(6-Methoxypyridin-3-yl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(4-Methoxy-3-methylphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5 dioxoimidazolidin-4-yl)-acetaimide, N-[5-(2,3-Dihydro-l-benzofuran-5-yl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5 dioxoimidazoiidin-4-yl)-acetaimide, 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{5-[3-(trifluorornethoxy)phenyl]-2,3-dihydro lH-inden-2-yl}-acetamide, N-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-lH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, N-[5-(4-Cyano-3-methylphenyl)-2,3-dihydro-IH-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2- {4-[4 (trigifluoromethyl)phenoxy]phenyl)ethyl)-acetamide, 2-(2.5-Dioxoimidazolidin-4-yl)-N-{2-[4-(4-methaoxyphenoxy)phenyl]ethyl}-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-{4-[4-(trifluoromethoxy)phenoxy]phenyl}ethyl)-acetamide, N-{2-[4-(4-chlorophenoxy)phanyl]ethyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide N-{2-[4-(4-Acetylphenoxy)phenyl]ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N- {2-[4-(pyridin-3-yloxy)phenyl]ethayl}-acetamide. 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2- {4-[(6-methoxypyridin-3-yI)oxy]phenyl}ethyl)-acetamide N- {2-[4-(4-Cyanophenoxy)phenyl]ethyl} -2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-(4-(4-methylphenoxy)phenyl]ethyl)-acetamide 2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(4-fluorophenoxy)phenyl]ethyl}-acetamide N-(2-Biphenyl-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide N-(2-(1,1-Biphenyl-4-yl)-2-methoxyethyl3-2-(2,5-dioxoimdazolidin-4-yl)-acetamide N-(2-(1,1 '-Biphcnyl-4-yl)-ethyI]-2-(2,5-dioxoimidazolidin-4-yl)-N-methylacetamide 2-(2,5-Dioxoimida2»lidin-4-yI)-N-[2-(4-phenylethynyI-piperidin-l-yl)-ethyl]-acetamide, N- {2-[(4-Bromobenzyl)oxy]ethyl} -2-(2,5-dioxoimidazolidin-4-yl)-acetamide, 2-(l, 1 '-Biphcnyl-4-yl)-2-oxoethyl {2,5-dioxoimidazoIidin-4-yl)acetate, and pharmaceutically acceptable salts and solvates thereof. 12. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises, reacting a compound of formula (Formula Removed) wherein X' represents an oxygen atom or a group NR4 and L, G2 and R4 are as defined in formula (I), with an activated carboxylic acid of formula (Formula Removed) and optionally after (a) forming a pharmaceutically acceptable salt or solvate. 13. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 11 in association with a pharmaceutically acceptable adjuvant, diluent or carrier, said compound being present in the range of 0.05 to 99% by weight. 14. A process for the preparation of a pharmaceutical composition as claimed in claim 13 which comprises mixing a compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof as defined in any one of claims 1 to 11 with a pharmaceutically acceptable adjuvant, diluent or carrier.

Documents:

450-delnp-2005-abstract.pdf

450-DELNP-2005-Claims.pdf

450-delnp-2005-complete specification (as,files).pdf

450-delnp-2005-complete specification (granted).pdf

450-DELNP-2005-Correspondence-Others-(31-03-2010).pdf

450-delnp-2005-correspondence-others.pdf

450-delnp-2005-correspondence-po.pdf

450-DELNP-2005-Description (Complete).pdf

450-delnp-2005-form-1.pdf

450-delnp-2005-form-18.pdf

450-DELNP-2005-Form-2.pdf

450-DELNP-2005-Form-3-(31-03-2010).pdf

450-delnp-2005-form-3.pdf

450-delnp-2005-form-5.pdf

450-delnp-2005-gpa.pdf

450-delnp-2005-pct-210.pdf

450-delnp-2005-pct-304.pdf

450-delnp-2005-pct-409.pdf

450-delnp-2005-petition-137.pdf

450-delnp-2005-petition-138.pdf

abstract.jpg